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Abstract
The thesis deals with the development of ”Predictive tools for designing new
insulins and treatments regimens” and consists of two parts: A model based
approach for bridging properties of new insulin analogues from glucose clamp
experiments to meal tolerance tests (MTT) and a second part that describes
an implemented software program able to handle stochastic differential equa-
tions (SDEs) with mixed effects. The thesis is supplemented with scientific
papers published during the PhD.
Developing an insulin analogue from candidate molecule to a clinical drug
consists of a development programme including different phases targeting
safety and efficacy. The focus of this thesis is the shift from Phase I, targeting
safety, to Phase II, targeting efficacy. An insulin analogue is typically tested
for safety in glucose clamp experiments in Phase I clinical trials and progresses
into Phase II where dose and efficacy are investigated. Numerous methods are
used to quantify dose and efficacy in Phase II - especially of interest is the
24-hour meal tolerance test as it tries to portray near normal living conditions.
Part I describes an integrated model for insulin and glucose which is aimed
at simulating 24-hour glucose profiles from a MTT with treatments based on
the new insulin analogue that previously only has been tested in clamps. The
bridge between insulin analogue properties determined in clamp experiments
to meal tolerance test outcomes in Phase II trials is not simple and is compli-
cated by shifts in experimental setup, time horizon and treatment regimen.
A bridging strategy was introduced where an integrated model simulating
MTTs was extended with models developed on clamp data that described PK
and PD for the new insulin analogue. The bridging strategy was tested by
building an integrated model based on human insulin trials which was then
evaluated using insulin Aspart (IAsp).
The integrated model was estimated in two separate sub models due to
computational complexity. Insulin model challenges were faced at the estima-
tion step regarding separability of insulin input pathways (exogenous/secretion)
which resulted in several fixed parameters but also an insulin delivery model as
opposed to a prehepatic insulin secretion model coupled with hepatic extrac-
tion. The glucose model was an extended version of the oral glucose minimal
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model [Man et al., 2002] which had a meal function incorporated.
The two sub models were combined into an integrated model which was
evaluated in different scenarios: An iso-glucaemic glucose clamp, an insulin
tolerance test and comparing derived measures of glucose effectiveness. The
model evaluation pinpointed insulin sensitivity issues which were accommo-
dated with a change in model building towards a more insulin sensitive model
type. Conclusively, the integrated model fitted estimation data well both for
insulin and glucose. Furthermore, the evaluation scenarios showed overall
correspondence with literature with only minor discrepancies.
The evaluation on insulin Aspart required a PK model for IAsp and a
model describing IAsp action in MTTs. The IAsp PK model was available
from a different Novo Nordisk project and the action transfer function was
estimated on cross-over clamp data with human insulin and insulin Aspart.
The two components were then embedded into the integrated model.
The extended integrated model was used to simulate 24-hour profiles of
insulin and glucose from meal tolerance tests including treatments with bipha-
sic insulin Aspart. The evaluation showed that the extended integrated model
was able to predict insulin levels reasonably both mean profile and variation
whereas glucose profiles were not predicted accurately.
Post modelling analysis targeting both insulin and glucose components
showed that preconditions for the bridging strategy which implied the use of
a mean IAsp PK model, could be the cause for the mis-predictions. Future
research should look into ways for individualising the insulin treatment when
no information on individual level is present.
The model building process could have benefitted from the use of SDEs.
Unfortunately, availability of a software program able to handle mixed effects
and SDEs resulted in a modelling approach based on ordinary differential
equations. The absence of such a program motivated the development of new
a tool with PK/PD features, SDEs and mixed effects.
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Part II presents a software package which was developed in order to be
able to handle SDEs with mixed effects. The package was implemented in
R which allowed for a single environment for data preparation, model build-
ing and results handling but also provided accessibility for users and ease of
installation.
The R-package implements the (Extended) Kalman Filter for handling
SDEs and uses the FOCE approximation to calculate the marginal likelihood
for parameters used in maximum likelihood estimation.
A number of applications of PSM are presented in which deconvolution is
the topic for most. Deconvolution based on SDEs was used to determine pre-
hepatic insulin secretion rates; hepatic insulin extraction rates using both in-
sulin and C-peptide measurements, and glucose appearance rates constrained
to be in the positive range in a simulated minimal model setting. More ap-
plications included an insulin secretion model based on an intervention model
type and an analysis of influence from input error propagation as estimated
with ODEs and SDEs.
KEY WORDS: Insulin, Glucose, Meal Tolerance Test (MTT), Compartment
Models, PK/PD modelling, Stochastic Differential Equations (SDEs), Mixed
Effects, NLME, FOCE, Extended Kalman Filter

Resume´
Denne PhD afhandling beskriver opbygning af en matematisk model til forudsigelse
af 24 timers glukose profiler fra m˚altidstests. Derudover vil implementeringen
af et program, som er i stand til at h˚andtere stokastiske differential ligninger
ogs˚a blive beskrevet. Afhandlingen er delt op i to tilsvarende dele og deru-
dover kan videnskabelige publikationer, som er tilvejebragt under PhD pro-
jektet, findes i appendiks.
Udviklingen af insulin analoger, fra kandidat molekyle til anvendeligt medicin,
sker gennem et udviklingsforløb inddelt i faser. Af særlig interesse for dette
projekt, er overgangen mellem fase I og fase II.
Fase I indeholder typisk clamp forsøg, hvori sikkerheden af insulin analogen
undersøges. Disse forsøg udgør en sikker platform men tilvejebringer kun lidt
information om virkningen af insulin analogen under normalt brug. Fase II er
m˚alrettet til at bestemme virkningen af insulin analogen og derigennem den
nødvendige dosering. Til dette anvendes ofte forsøg, hvori langtidseffekterne
kortlægges. I særlige tilfælde kan 24 timers m˚altidstests bruges til at give en
præcis beskrivelse af insulin/glukose forløbet over en hel dag for en patient.
Overgangen fra fase I til II udgøres alts˚a af et spring i tidshorisont, antallet
af doser, og m˚aske vigtigst selve testsetuppet. En matematisk model, som er
i stand til at hjælpe i beskrivelsen af en insulin analogs egenskaber vil være
til stor hjælp i fastlæggelsen af fase II forsøg.
Del I i afhandlingen præsenterer en matematiske model, som skal hjælpe
med at bygge bro mellem egenskaber, som kan fastlægges i clamp-forsøg til ul-
timativt at forudsige resultaterne af 24 timers m˚altidstests udført med denne
nye insulin analog. Modellen skal baseres p˚a tidligere udførte m˚altidstests
samt indeholde en metode, hvorved insulin analogens egenskaber kan indar-
bejdes.
Kompleksiteten af modellen for insulin og glukose gjorde, at modellen blev
delt i to separate modeller, som skulle estimeres adskilt.
Estimeringen af insulin modellen blev i første omgang simplificeret ved
at benytte deconvolution til at bestemme præ-hepatisk sekretions rater for
insulin, som derved kunne kobles med hepatisk ekstraktion. Denne model
opbygning skulle sammenkobles med en absorptionsmodel for administreret
insulin, som ikke kan adskilles i m˚alingerne. Absorptionsmodellen best˚ar af
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en sekventiel struktur, som indeholder et delay kompartment for at opn˚a ov-
erensstemmelse med m˚alingerne. Denne model konstruktion blev evalueret i
en række test scenarier, hvor forskellige dele af modellen kunne sammenlignes
med resultater fra litteraturen.
Disse scenarier afdækkede en lav insulin følsomhed, som resulterede i en
række ændringer i modellen. En del af estimations datasættet blev eksklud-
eret, og model strukturen blev ændret til en insulin model, som ignorerede
hepatisk ekstraktion. Den nye model udnyttede ikke C-peptide ma˚lingerne,
men var simplere og var i god overensstemmelse med m˚alingerne.
En tilsvarende glukose model blev opbygget, som baserede sig p˚a den oral
minimal model [Man et al., 2002], som er en videreudvikling af Bergmans min-
imal model. Modellen inkluderede en m˚altidsfunktion, som beskrev glukose
optræden i plasma efter indtagelse af m˚altider.
Flere parameter blev fastsat jævnfør litteraturen i stedet for at blive es-
timeret for at stabiliserer parameter estimationen. Dette gjaldt b˚ade for in-
sulin og glukose modellen.
De to modeller blev sat sammen og brugt til at forudsige selv samme data,
som de var blevet estimeret p˚a. Dette for at verificere, at den adskilte esti-
mation ikke havde nogen indvirkning. Derudover blev de testet i de tidligere
nævnte test scenarierne (clamp og insulin tolerance test) for at bedømme ov-
erensstemmelse med uafhængige resultater fra litteraturen.
For at teste anvendeligheden af modellen i klinisk udvikling af insulin
analoger, blev modellen brugt til at forudsige 24 timer profiler af insulin As-
part. Den integrerede model for insulin og glukose blev udvidet med en PK
model for insulin Aspart samt en model, som oversatte insulin Asparts virkn-
ing til tilsvarende virkning for human insulin.
De forudsagte glukose profiler, baseret p˚a modellen udvidet med nye mod-
uler for insulin Aspart, var ikke i overensstemmelse med de m˚alte profiler. De
m˚alte profiler havde en stigning i glukose niveauerne henover natten, som ikke
blev matchet af forudsigelserne.
En række analyser undersøgte potentielle fejlkilder i modellen. I første
omgang blev det forsøgt at erstatte insulin modellen for insulin Aspart med de
m˚alte koncentrationer. Derefter blev det undersøgt om parametriseringen af
m˚altidsfunktionen kunne have haft en indvirkning. Til sidst blev fleksibiliteten
i minimal modellen undersøgt. Ingen af undersøgelserne var i stand til at
afdække præcist, hvor problemet l˚a.
En afsluttende analyse, som blev udført undervejs i selve sammenfatnin-
gen af afhandlingen, benyttede de individuelt m˚alte total koncentrationer til
at erstatte hele insulin modellen i simulations modellen. Profilerne fra denne
model var gode og viste at problemet meget vel kunne være brugen af gennem-
snitsprofiler. Gennemsnitsprofiler blev benyttet for at holde informationer fra
clamp til m˚altidstests adskilte.
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Konklusionen p˚a den matematiske model var, at den ikke var i stand til
at danne bro mellem clamp egenskaber og resultater i m˚altidstests, men at
enkeltmodellerne kunne beskrive data ganske godt og var i overensstemmelse
med litteratur resultater.
Del II af afhandlingen omhandler udviklingen af PSM - en R-pakke, som
kan h˚andtere stokastiske differential ligninger i kombination med mixed effects.
Andre tilgængelige programmer kan ikke h˚andtere denne kombination med
undtagelse af en eksplicit implementering af Kalman Filteret i NONMEM.
Programmet benytter Kalman filteret til state estimering i de stokastiske
differential ligninger og FOCE approksimationen til at udregne likelihood
funktionen for mixed effects delen.
Programmet henvender sig til nye brugere, idet det er nemt tilgængeligt i
R, samt at der er skrevet brugermanualer og givet eksempler p˚a normal brug.
Implementeringen i R hindrer muligvis anvendelsen p˚a stor-skala problemer,
men gør til gengæld programmet vidt tilgængeligt. Dermed sigter programmet
mere p˚a en nemmere indgangsvinkel til modellering med stokastiske differen-
tial ligninger og mixed effects.
Til sidst præsenteres en række anvendelser af PSM herunder bestemmelse
af præ-hepatiske sekretionsrater for insulin og bestemmelse af glukose appear-
ance rater efter et m˚altid begrænset til det positive domæne. Et eksempel p˚a
en analyse af fejl udbredning fra input analyseret med ordinære og stokastiske
differential ligninger er ogs˚a præsenteret.
PhD projektet har spændt vidt og afdækket b˚ade matematisk modellering
samt udviklingen af at software program. Det endelig m˚al med den matem-
atiske modellering blev ikke n˚aet, men mange nyttige delm˚al blev n˚aet og
problemstillinger afdækket.
PSM er endnu et nyt program, s˚a udbredelsen af pakken kan endnu ikke
kortlægges. Programmet har potentialet til at blive brugt i undervisnings- og
forsknings-øjemed, hvorved form˚alet med programmet vil være opfyldt.
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Thesis Introduction
The title of the PhD thesis is: ”Predictive tools for designing new insulins and
treatment regimens” and covers a description of a 24-hour model for insulin
and glucose and an implementation of an R package able to handle stochastic
differential equations in a mixed effects setting. The two distinct parts are
described in separate parts in this PhD thesis.
Part I
The first part covers a project, where PK/PD modelling techniques were used
to bridge insulin properties from glucose clamp experiments into 24-hour pro-
files of glucose from a 24-hour meal tolerance test. The main topics of this
part are: Insulin and glucose model building based on ordinary differential
equations, utilising insulin analogue properties established in glucose clamp
experiments in simulations of a 24-hour meal tolerance test, external evalua-
tion of insulin and glucose models with literature results.
Part II
The second part describes an R package that was developed in collaboration
with Stig Bousgaard Mortensen. The package contains functionality for model
building with stochastic differential equations extended with mixed effects.
The package implements the Kalman filter and uses the FOCE approximation
to evaluate the marginal likelihood for the parameters. The motivation and
methodology for the package is described along with the different components
of the package.
A series of applications of the PSM package is presented that illustrates
the strengths of modelling with stochastic differential equations extended with
mixed effects such as deconvolution and handling of model misspecification.
1

Part I
Modelling Insulin and
Glucose
3

CHAPTER 1
Introduction
The main goal of the current PhD thesis is a development of ”Predictive tools
for designing new insulins and treatment regimens”. This part of the PhD
thesis will describe the model building - leading to a mathematical model
that ultimately can be used to predict outcomes of new insulin treatments.
Problem
The development of new insulin analogues is a vital component for a con-
tinued optimisation of treatments for diabetes. Various development paths
are being explored but relevant for this thesis is the development of new in-
sulin analogues with improved properties such as faster absorption or slower
elimination allowing a more convenient treatment for the patient and/or an
insulin profile closer to the insulin profile of a healthy person. The heteroge-
neous facets of diabetes with multiple causes and symptoms are in this thesis
limited to patients with type two diabetes mellitus (T2DM).
The development of insulin analogues starts by investigating insulin can-
didates in cell cultures and progresses in animals until eventually being tested
in humans. The drug development in humans is referred to as clinical de-
velopment and is divided into different phases. Relevant for this thesis are
phase I and II where safety and then efficacy are investigated. Phase I trials
aim at establishing safety for the insulin candidate and are often performed
in glucose clamp experiments in which the insulin analogue can be tested in
a safe environment for the test subject. Phase II targets the efficacy of the
insulin candidate in near-normal conditions.
In parallel with the safety assessment in glucose clamp experiments, the
pharmacokinetic (PK) and pharmacodynamic (PD) properties of the new in-
sulin analogue are also explored. A glucose clamp consists of an adjustable
continuous intravenous infusion of glucose used to maintain a predefined glu-
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cose concentration. The infused glucose profile reflects the glucose utilisation
at the predefined glucose level. The surplus in infused glucose needed to
maintain the glucose level after an insulin injection reflects the action of the
injected insulin [Heinemann, 2004]. Concentration measurements of the in-
sulin analogue during the clamp hold important pharmacokinetic information
that will be used in the bridging.
After a successful safety evaluation, phase II trials can be initiated. The
efficacy and safety of the insulin analogue is typically being assessed by mea-
sures of the surrogate marker glycated haemoglobin (HbA1c) which quantifies
glucose concentrations for last couple of months and records of adverse events
caused by hypoglycaemia. A comprehensive method used to investigate in-
sulin and glucose excursions over 24 hours is the 24-hour meal tolerance test
(MTT) which is a scenario mimicking near-normal conditions for a patient
over 24 hours with inclusion of meals. Glucose and insulin profiles are mea-
sured and used to evaluate the treatment regimen - potentially compared to
a cross-over treatment in order to determine an optimal treatment regimen.
The design of a 24-hour meal tolerance test in phase II trials should be
based on information from phase I but it is not simple how to translate and
incorporate acquired information. A quantitative integrated model for insulin
and glucose that bridges clamp determined properties into 24-hour glucose
profiles could be a useful tool for designing better trials and ultimately used
to predict HbA1c endpoints for an insulin analogue treatment regimen.
Hypothesis
The project hypothesis is that a mathematical model can be determined that
is able to characterise insulin and glucose dynamics for a T2DM population in
a 24-hour meal tolerance test where insulin treatment is based on injections
of the new insulin analogue.
The integrated model should include facilities to embed new insulin ana-
logues in order to simulate new treatments. The inclusion of a new insulin
analogue requires a PK model for the new analogue but also a link for the
new insulin analogue such that insulin analogue action can be included into
the model.
Project Goal
The project goal is to develop a functional model which can be used in clinical
development to bridge information from clamp experiments to 24-hour meal
tolerance tests. An integrated model of insulin and glucose will aid in designing
and optimising treatment regimens: no. of doses, dose level, ratios of insulin
mixtures, measurement timing.
The primary outcome from a model prediction is the 24-hour mean glu-
cose profile with corresponding variation. The variation will be based on the
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differences between the individuals in the simulation population.
However, the specific glucose profile for a treatment can be difficult to pre-
dict as baselines values can drift. A secondary objective is the prediction of
difference in glucose profiles between two different treatments. By predicting
differences in glucose levels, the glucose baseline value should be circumvented.
The goal is optimistic as traditional insulin/glucose models only cover
shorter time periods and usually only a single glucose tolerance tests (IV,
oral or meal). Furthermore, the target population of T2DM patients adds
complexity to the model as residual insulin secretion is still present as opposed
to T1DM patients.
Collaboration
The modelling project was carried out in collaboration with DTU-IMM and
Novo Nordisk A/S. The project group and collaborators consisted of: Niels
Rode Kristensen, Rene´ Normann Hansen, Rune Viig Overgaard, Steen Hvass
Ingwersen, Morten Colding-Jørgensen, Henrik Madsen and Roman Hovorka.
Andreas Velsing Groth and Lene Alifrangis provided a PK model for in-
sulin Aspart. Claudio Cobelli and Chiara Dalla Man contributed to an analysis
of glucose apperance rates.
The modelling task lasted from July 2006 and onwards and is a pivotal
piece in the puzzle that should constitute a PhD thesis.

CHAPTER 2
PK/PD Modelling
A brief introduction to pharmacokinetic (PK) and pharmacodynamic (PD)
modelling and related concepts is presented here to form a knowledge base for
the modelling performed in this thesis. A more detailed PK/PD introduction
was written during the PhD and can be found in Paper C.
The class of PK/PD models described here are semi-mechanistic mathe-
matical/statistical models aimed at descriptive/predictive purposes with pa-
rameters driven by data i.e. a model with internal processes in alignment with
a priori physiological knowledge and with a physiological interpretation of pa-
rameters. Overall a definition close to the definition proposed by Aarons et al.
[2001] but loosened as drugs are extended to included endogenous substances
as well.
Pharmacokinetics describes the relationship between drug inflow and re-
sulting concentration. The concentrations can be blood concentrations but the
point of interest could also be related to the site of action e.g. bone marrow
or cerebrospinal fluid. The processes included in PK modelling are charac-
terised by absorption, distribution, metabolism and elimination. Absorption
describes the movement from dosing site to systemic circulation. Intravenous
dosing as opposed to oral dosing gives a different absorption pattern and
should be modelled accordingly. The distribution of drug into other tissues
such as fat or muscle is crucial to link dose to concentrations. Metabolism
describes the conversion of drug into active or in-active metabolites typically
by the liver. Finally, elimination describes the irreversible removal of drug
from the body e.g. via the kidneys. The hierarchy of processes can be used
as a framework to approach modelling systematically.
Pharmacodynamics describes drug effects over time and relates the drug
concentrations to drug effects. Whereas concentrations are often measured
on a continuous scale, this is not the case for pharmacological response which
may also be binary, categorical and frequently measured on subjective scales.
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PK/PD modelling aims at linking dose-exposure-effect into a single model
that can be used for exploratory/confirmatory purposes. PK/PD modelling
is a versatile and important tool in the learn-confirm cycle in clinical devel-
opment [Sheiner, 1997; Sheiner and Steimer, 2000], especially for acquiring
information and planning trials.
2.1 Compartmental Models
The mathematical models used in PK/PD modelling are often in the form of
compartmental models also denoted state space models. Each compartment
represents a specific state for the drug being that chemical, physical, or spatial
state. The drug within a compartment is assumed to be homogeneous leading
to a common set of properties for that specific state. Often states can be
joined if properties are nearly identical or inseparable.
The transformation from one state to another is modelled with fluxes be-
tween compartments. The outgoing flux is often modelled as being propor-
tional to the amount in the compartment but both simpler and more advanced
fluxes can also used. A compartment model can be specified using differential
equations describing the changes in states using the fluxes.
This compartment specification enables statistical tests to determine the
functional form of the processes. The test can focus on the number of compart-
ments or complexity of fluxes. The modelling can thus be used to determine
influential factors or provide information on the involved processes.
The internal drug states are often non-observable and insight into the
system is solely based on noisy observations. The estimation challenge lies in
determining system parameters when only partial insight is possible further
complicated by measurements error.
The observation link in the model describes the assumed behaviour of the
noise. This is often referred to as the error model. The simplest used error
models are the additive or proportional but much more complex structures
utilising input and correlation could also be used.
The compartmental approach often enables a physiological interpretation
of the parameters in relation to described processes. The ability to link pa-
rameters to physiology is a powerful feature of compartmental modelling.
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2.2 Population Model
The term population model denotes a hierarchical division of the variation
observed in trials. The division of variation can described from population to
individual as:
Inter-individual variation (IIV) is described using an individual effect on
parameter resulting in a distribution for the parameter.
Within Individual variation is quantified using a mathematical model that
describes the PK/PD profile for the specific individual.
Residual variation is the remainder of variation that the within individual
model cannot explained. A characterisation of the residual structure is
required.
The population model approach allows for simultaneous estimation across
individuals. This joint estimation enables a more robust parameter estimation
but also serves useful in the case of sparse sampling where the within individual
model is unidentifiable.
The hierarchy can be replaced and/or extended with inter-occasion (IOV)
or inter-trial variation to accommodate multiple visits or data originating from
different trials.
The theory of population modelling comes from the statistical mixed effects
theory where responses, typically of repeated measurements, are modelled
using fixed and random effects. In the population modelling scheme the fixed
effects are denoted population parameters and random effects are used to
account for the population’s variation on parameters. As many physiological
parameters are bound to be in the positive range, the distributions of the
parameters are often assumed to be log-normal. The implementation of inter-
individual variation on a parameter is thus often modelled as:
φ = θ · exp(η) (2.1)
where φ represent the individual parameter and θ is the population value of
the parameter. η is assumed to be Gaussian with variance Ω.
The formulation in Equation (2.1) allows for the inclusion of covariates
(e.g. weight, BMI, creatinin clearance) to describe parameter variation.
The PK/PD modelling framework based on semi-mechanistic, data driven
models combined with the population approach provides a versatile platform
for descriptive and predictive analysis in clinical drug development. An in-
creased popularity can also be observed in the range of programs supporting
the methodology (NONMEM, Monolix, SPK) and also in the FDA guideline
for population pharmacokinetics [FDA, 1999].

CHAPTER 3
Glucose, Insulin, and Diabetes
This chapter will cover a short introduction to insulin and glucose - namely
their roles in healthy subjects but also the disorders arising in diabetes. Focus
is devoted to processes and concepts in order to form a basis for the model
building.
3.1 Glucose and Insulin
Glucose is the main source of energy in the human body and is either ingested
via meals or synthesised in the liver. The main role of glucose is to function
as fuel for muscle, adipose tissues and most importantly the brain. The brain
has a constant consumption of glucose regardless of availability whereas other
tissues can adjust to low levels of glucose and even switch to lipids. The
lack of glucose supply to the brain can cause unconsciousness or in extreme
cases death. This condition is called hypoglycaemia and is feared by diabetic
patients.
Hyperglycemia is the opposite condition where glucose concentrations are
too high. Severe hyperglycemia can lead to ketoacidosis resulting in coma
whereas moderate hyperglycemia has no immediate consequences but have a
wide range of long term complications related to micro- and macro-vascular
degradation. The most frequent complications are: cardiovascular diseases,
renal failure, retinal damages, and nerve damages.
In healthy subjects, glucose is regulated within tight boundaries such that
these complications do not occur. The two most important hormones used
for the control are insulin and glucagon. In short, the control mechanism can
be explained as: insulin decreases glucose concentrations whereas glucagon
increases glucose concentrations.
The main pathway for glucose in the human body originates from oral
intake i.e. meals. The shifts between intake of meals and fasting periods imply
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a constant regulation of glucose. When a meal is ingested, it passes through
the gastro-intestinal tract where nutrients such as carbohydrates are degraded
and pass through membranes into systemic circulation. The incoming glucose
needs to be stored for fasting periods or utilised as energy immediately. Insulin
facilitates/accelerates processes that eliminate glucose from blood either for
storage purposes or immediate use. These processes occur in both muscle and
adipose tissues but the main storage for glucose is the liver. The liver stores
glucose by converting it into glycogen that at a later stage can be converted
back into glucose. In short, insulin both promotes an increased storage of
glucose and an increased utilisation of glucose.
Glucagon increases glucose levels by initiating processes that breakdown
glycogen to glucose, decrease the storage of glucose and decrease the utilisation
of glucose. The combination of increased input and lowered elimination results
in increasing levels of glucose.
Both glucagon and insulin are produced in the pancreas, in the α- and β-
cells respectively. These cells reside in regions that in a microscope resemble
islands - hence the name ”The islets of Langerhans”. The main driver for
secretion is the glucose concentration such that for a low glucose level glucagon
is secreted and for a high glucose level insulin is secreted.
Insulin is secreted in a biphasic pattern denoted first and second phase.
The first phase is a pulse of insulin from the pre-packaged vesicles with insulin
ready for secretion in the β cells. The second phase secretion comes from an
increased production of insulin which is a delayed process compared to the
first phase secretion.
The appearance of food in the intestines triggers a class of hormones known
as incretin hormones to be secreted. The incretin hormones have a boosting
effect on the insulin secretion that can best be observed by comparing an IV
infusion of glucose mimicking glucose concentrations seen after an ingestion
of a meal. The insulin response from the oral intake is much larger than the
IV insulin concentration.
A by-product from the insulin secretion is a peptide that comes from the
precursor to the insulin molecule. This peptide originates from the precur-
sor to insulin named proinsulin which is split into insulin and C-peptide in
equimolar amounts at secretion. Insulin suffers from a large first pass effect in
the liver i.e. large amounts of secreted insulin do not reach systemic circula-
tion. Conversely, C-peptide is eliminated via kidneys and with longer half-life
than insulin thereby making it a reliable marker for insulin secretion. The
effects of C-peptide have long been assumed to be non-existent but recently a
preventive effect of complications have been observed [Marques et al., 2004].
The glucose regulation for healthy subjects result in tightly controlled
glucose concentrations that guaranties glucose supply to the brain and avoids
long term complications. Several diseases can affect the glucose homeostasis
but relevant for this thesis is diabetes which is the topic of the next section.
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3.2 Diabetes
Diabetes is the commonly used name for the disease: diabetes mellitus which
is characterised as a metabolic disorder. Diabetes spans a mixed group of dis-
orders that all are manifested by hyperglycemia as a result of insulin resistance
and/or decreased insulin secretion.
The focus on diabetes has increased over the last years partly due to the
epidemic development in diagnosed subjects. The world health organisation
has estimated the prevalence of diabetes to double from 2000 to 2030.
year 2000
171, 000, 000
−→ year 2030
366, 000, 000
WHO has also estimated that 2.9 million people died in 2005 as a consequence
of diabetes or related diseases [WHO, 2008].
The most common types of diabetes are: Type I and Type II which share
complications but due to different causes.
Type I Diabetes Mellitus (T1DM) is an auto immune disease where the
immune system attacks β cells in the pancreas. The result is a complete
halt in insulin production. The patients’ cells will starve unless insulin
is administered making the patient completely dependent on insulin in-
jections.
Type II Diabetes Mellitus (T2DM) is caused by insulin resistance which
causes a lowered effect of insulin. Typically, this lowered effect can be
compensated by an increased insulin secretion. T2DM was previously
predominately seen in elderly but recently diagnosis in children has be-
come more frequent.
T1DM patients rely on injections of insulin to survive as a replacement
for the endogenous production of insulin. T2DM patients are initially treated
with diet and exercise, potentially supported by medication that enhances
insulin sensitivity or secretion. However, β cells gradually deplete leaving
T2DM patients dependent on injections of insulin.
3.3 Insulin Treatments
The goal of the insulin therapies is to replace/supplement the secretion of
insulin. The target for the insulin treatment is to obtain an insulin profile
as close to a healthy secretion profile as possible. The healthy profile can
be described as a basal overall coverage with prandial peaks. A treatment
that mimics this pattern is named basal+bolus as a set of injections accounts
for basal coverage and bolus injections at meal times accounts for prandial
16 3.3. Insulin Treatments
insulin responses. The insulin injections are usually subcutaneous which are
relatively simple for the patient to self-administer.
Synthetic insulin is produced by recombinant DNA technology during
which the properties of the insulin can be slightly altered. These analogues
are typically focussed on new properties such as faster absorption or slower
elimination.
The thesis includes data from many different trials where different insulin
treatments are used. The next sections will describe different insulin types
and treatments.
Human Insulin
Synthetic human insulin is a common insulin type used in treatments. It is
identical to endogenously secreted insulin and will in this thesis simply be
denoted as human insulin (HI).
Human insulin is administered via subcutaneous injection and starts work-
ing within 30 minutes. The delay requires certain timing in relation to meal
injections where a healthy insulin response is almost immediate.
An often used insulin complex based on human insulin is called NPH1 and
has a slower absorption into systemic circulation. The complex is formed by
combining human insulin, protamine and zinc which creates a crystal that is
poorly absorbed and needs to dissolve before human insulin can pass into cir-
culation. The crystallised version of human insulin is also called protaminated
human insulin and is classified as intermediate-acting insulin.
A premix combination of normal human insulin and NPH provides a com-
pound for a single injection with a component for fast absorption and a com-
ponent for slower absorption. The premix compound is also known as biphasic
human insulin (BHI) and is available in different mix ratios e.g. 30% human
insulin and 70% NPH which is denoted BHI30. Biphasic human insulin is
marketed Mixtard from Novo Nordisk A/S but other companies have similar
products.
Insulin Aspart
Insulin analogues are as already mentioned synthetic insulin where alter-
ations/replacements have been made to the amino acid sequence. By replacing
amino acid(s) in the insulin molecule, the analogue acquires new properties.
Insulin Aspart is such an insulin analogue where absorption properties
have been improved but in plasma the properties are identical to human in-
sulin. This makes insulin Aspart a rapid-acting insulin analogue that starts
working within 5-15 minutes. The fast absorption makes insulin Aspart ideal
for prandial injections where a rapid increase in insulin is desired. The Novo
Nordisk product name for insulin Aspart is NovoRapid.
1Neutral Protamine Hagedorn named after the inventor Christian Hagedorn (1888-1971)
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Similar to human insulin, is Insulin Aspart combined with protamine in
order to create a slower release from injection depot. Insulin Aspart and
protaminated insulin Aspart is combined into a premix of biphasic insulin
Aspart (BIAsp). The mixture ratios are similar to BHI and with same syntax.
BIAsp30 consists of 30% insulin Aspart and 70% prominated insulin Aspart
and is marketed from Novo Nordisk as NovoMix30. NovoMix is in this thesis
often abbreviated to NM such that NovoMix30 is denoted NM30.
New Analogues
Current research aims at properties which provide faster absorption into cir-
culation but also at obtaining slower elimination from plasma.
The new properties will enable insulin that has reduced delay which would
be advantageous for bolus doses at meals or long acting analogues which could
cover basal levels over longer time periods.
Insulin Treatments
In this thesis a range of treatment regimens are encountered in trials and
simulations which are listed here:
BHI30
A single injection of human insulin premix 30% normal and 70% slow
acting.
BIAsp30
A single injection of insulin Aspart premix 30% normal and 70% slow
acting.
BHI30 (2xdaily)
Two daily injections of a human insulin premix of 30% normal and 70%
slow acting. The injections are given at breakfast and dinner.
BIAsp30 (2xdaily)
Two daily injections of a insulin Aspart premix of 30% normal and 70%
slow acting. The injections are given at breakfast and dinner.
BIAsp707050
is a compact notation for three daily injections with insulin Aspart pre-
mix. The breakfast and lunch injection is BIAsp70 (70% fast) and a
dinner injection with BIAsp50.
BIAsp707070
is a compact notation for three daily injections with insulin Aspart pre-
mix. Injetions at breakfast, lunch and dinner all with BIAsp70.
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With a basic understanding of insulin, glucose and insulin treatments; the
focus is now turned towards building an integrated for insulin and glucose.
CHAPTER 4
Integrated Model Setup
The main objective of the PhD project has been to develop a mathematical
model able to predict insulin and glucose profiles for T2DM patients examined
in 24-hour meal tolerance tests (MTT). The simulated insulin treatments are
based on properties of new insulin analogues that have only been evaluated in
glucose clamps experiments. The properties of the analogue should be bridged
from clamp into a 24-hour MTT model.
The insulin part of the model should thus be interchangeable such that new
insulin analogues can be embedded in the integrated insulin/glucose model.
The final outcome of the model simulation should be 24-hour profiles of glucose
and insulin.
An integrated model of insulin and glucose can provide valuable informa-
tion in trial design optimisation by quantifying ”what if”-scenarios such as
”How much would an additional insulin injection improve glucose control?”
Mathematical modelling of insulin/glucose experiments has mainly been
used to describe experiments such as intravenous glucose tolerance tests (IVGTT)
or oral glucose tolerance tests (OGTT). The experiments constitute a safe
setup and procure important information on tested insulins. The scenarios
are unfortunately relatively unphysiological and little is learned on how the
insulins will perform under normal patient conditions. 24-hour meal tolerance
tests are occasionally included in phase II programmes in order to compre-
hensively investigate treatments in near realistic conditions.
Multiple mathematical models have been published that describe IVGTT
and OGTT with different goals and substantially varying assumptions - see
review by Landersdorfer and Jusko [2008]. The modelling of 24-hour data is
more complicated as meals and diurnal variation needs to be accounted for.
During the PhD programme two models for insulin and glucose were published
by other groups that targeted 24-hour modelling of insulin and glucose. One
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by Silber et al. [2007]; Jauslin-Stetina [2008] and another by Man et al. [2007b].
The two models will be discussed in Chapter 10.
4.1 Bridging Strategy
The notion of bridging characterises the integration of insulin properties mapped
in clamp experiments into a model able to simulate 24-hour glucose concen-
tration profiles from meal tolerance tests. The new insulin analogue will po-
tentially have different properties in relation to absorption, disposition and/or
action compared to the human insulin.
Preconditions
In order for such a model to be applicable in the development process of new
insulin analogues, it needs to adhere to a specific flow of information.
The dynamics and variation seen in historic 24-hour glucose profiles should
form the basis for the model predictions and used as foundation. The aim of
the model is to predict the population mean response i.e. glucose profile and
implicitly insulin profiles but also corresponding variation. The model should
allow for inputs on treatment regimen or trial setting e.g. dose sizes, insulin
mixture, injection times, and meal sizes in order to be sufficiently flexible to
simulate different MTT setups.
A link needs to be established for insulin analogue action between clamp
and MTT as the insulin action occurs in a previously untested setting. The
only knowledge on the insulin analogue action originates from clamp profiles
and should be translated into insulin action during an MTT. The common
ground is via human insulin which is often used as comparator treatment
in cross-over design in clamps and inevitably also present in T2DM patients
during an MTT due to residual insulin secretion. The reference insulin in the
model will thus be human insulin. The insulin analogue action needs to be
translated into insulin action in the model which was measured with human
insulin concentrations.
The prediction of the variation in the meal tolerance test should origi-
nate from simulation with an entire population. The model should include a
population of individuals that correspond to the typical population recruited
for a 24-hour MTT trial. A typical trial simulation would randomly created
the population from variation patterns estimated in the historic data but a
drawback of sampling a population is the potential range of unphysiological
test subjects. In order to guaranty a physiological plausible population, the
model population should be generated by ”cloning” test subjects. The model
population should thus consist of a plausible population of T2DM patients
where knowledge on the new insulin analogue needs to be mean population
parameters.
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The clamp experiment should thus be used for a derivation of a insulin
analogue PK model and a transfer function that translates the insulin analogue
action into action in a human insulin model.
PK Model
The PK model for the insulin analogue should be estimated on the PK data
from the clamp experiments. The absorption and disposition model should
be able to extrapolate to new treatment regimens with changed doses, insulin
mixture ratios and dosing time points. However, the PK model is constrained
to a mean population model as no knowledge is available for the estimated
subjects in integrated model based on human insulin.
Transfer Function
The action of the insulin analogue has not been tested in meal tolerance tests
and also not in the subjects that the integrated model was estimated on. The
action of the insulin analogue should thus be converted into a useful measure
in the integrated model - human insulin concentrations. The action of the
insulin analogue have been compared to human insulin action in a cross-over
design which enables a mapping of the analogue effect relatively to human
insulin.
The transfer function simply calculates the action equivalent concentration
of human insulin for the new insulin analogue. The transfer function will be
unique for each insulin analogue and requires a cross-over comparator with
human insulin. As with the PK model the transfer function can only be
population model as no individual information can be bridged.
The general setup for the transfer function should include capabilities to
accommodate faster absorption and slower elimination for new insulin ana-
logues. The transfer function is pivotal for a correct simulation of the effects
of a new insulin analogue as an erroneous translation of effect invalidates the
simulation.
Modelling methodology for the transfer function is a PID approach namely
a function of a proportional, a delayed and a derivative signal from the insulin
analogue profile. The abbreviation PID denotes proportional, integral and
derivative and is a well known technique in signal processing and time series
analysis.
The bridging strategy ultimately requires the components: an integrated
model for insulin/glucose, an insulin analogue PK model, and an insulin ana-
logue transfer function. The next section will describe the general setup for
an integrated model for insulin and glucose.
22 4.2. High Level Model Description
4.2 High Level Model Description
The integrated model is aimed at simulations beyond its estimation basis.
An empirical modelling approach would only serve a descriptive purpose but
is not useful in an extrapolation setting. The simulation with new insulin
analogues requires that model dynamics resemble actual occurring processes
in meal tolerance tests.
A schematic model formed the basis for a description of individual compo-
nents that spanned relevant processes from a PK/PD framework viewpoint.
Several modelling approaches exist with specific focus areas: Mechanism-
based [Mosekilde et al., 2005], empirical/black-box, grey-box [Tornøe et al.,
2004] and parsimonious modelling [Feng, 2008] etc.
The important point was that the model should be “as simple as possible -
but not simpler”1 - preferably with parameters driven by data, and with model
dynamics that were in correspondence with prior physiological knowledge.
Ideally, the parameters in the model should be estimated from data but
in cases where a parameter is unidentifiable, a literature value will be used
instead.
The relationships between insulin and glucose and corresponding input
pathways are shown in Figure 4.1. The figure shows the basic relationship
where insulin promotes glucose elimination and glucose triggers insulin se-
cretion. Three different insulin treatments are shown in gray boxes which
represents the interchangeable property. The influx of glucose from meals is
also shown.
Insulin GlucoseHumaninsulin Meals
Insulin
Aspart
New
Insulin
Analogue
Insulin Secretion
Glucose Elimination
Figure 4.1: Model with an interchangeable insulin component
Identifiability issues are inevitable to arise when working with large state
space models especially with multiple input/output pathways. Identifiability
issues will not be analysed with analytical or numerical methods [Cobelli and
DiStefano, 1980] but primarily be assessed subjectively.
1Quote from Albert Einstein: Everything should be as simple as possible - but no simpler
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Components
The main components in the model are insulin, glucose, their relationship and
appearance of injected insulin and ingested glucose. The model will focus on
meals and insulin as main factors for glucose excursions - other hormones and
lipids are not included in the model but their effects will inherently be lumped
into the estimated model dynamics.
Current state of the art models will be used to form an initial integrated
model. The models will be found in literature and attention should be on
ensuring similarity in population and scenario between the modelling target
and literature. In short, preferably only results based on 24-hour MTTs and
T2DM patients should be used.
A more detailed overview of the integrated model displayed according to
PK/PD concepts is shown in Figure 4.2 where arrows represent both fluxes
and influences.
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Figure 4.2: Schematic model
Insulin Model
The administered insulin treatment is shown in the lower left corner which
gives rise to an inflow of insulin. The regimen covers: choice of insulin (ana-
logue), injection time points, biphasic mixture ratios and insulin doses. The
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set of predefined insulin covariates naturally affects the insulin concentration
and needs to be included. The insulin absorption component contains three
boxes representing different insulin (analogues) to illustrate that the differ-
ent insulin analogues can have different properties and consequently different
models.
The PK model for injected human insulin was estimated simultaneous with
the integrated model but models for a new insulin analogue (insulin Aspart)
was plugged in - in order to adhere to the bridging strategy.
The population of T2DM subjects requires the inclusion of insulin secretion
as opposed to modelling T1DM populations where no secretion is present.
The varying degrees of residual insulin secretion and/or changes in insulin
sensitivity should be allowed for in the model setup i.e. in the insulin secretion
model and the insulin action model.
The insulin secretion model was assumed to be glucocentric, omitting other
effects such as nerve signals and free fatty acids. The model for insulin secre-
tion can be approached in two different ways which will be elaborated in the
chapter on insulin model building (page 31).
Glucose Model
The glucose part of the model consists of glucose absorption from meals and
glucose disposition which includes insulin dependent elimination. The glucose
absorption model translates the ingested meal into a glucose appearance pro-
file that enters the disposition model. The covariates characterising a meal
are: serving time, energy content and meal composition. The volume of distri-
bution for the disposition of glucose should reflect relevant tissues and fluids.
The elimination of glucose should mimic the processes present during a
MTT. Typically, glucose elimination is divided into two parts: insulin in-
dependent and insulin dependent elimination.
The relation between insulin and glucose is included as insulin action model
in the glucose model and as glucose influence on insulin secretion in the insulin
model.
Integrated Model
The general modelling methodology was based on the population model where
the dynamical system is specified using ordinary differential equations (ODEs)
extended with mixed effects. The setup is widely used within PK/PD mod-
elling and holds the features of being semi-mechanism based and allowing for
inter-individual variation. NONMEM V [Sheiner and Beal, 1994] was used for
parameter estimation and simulation.
The multivariate complexity of the integrated model resulted in a sub-
stantial computational load additionally complicated by limitations in the
NONMEM installation. The problems finally led to a decision to separate
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the parameter estimation into two sub models: an insulin sub model and a
glucose sub model. The insulin sub model was estimated using the observed
glucose concentrations as input and vice versa with the glucose sub model.
A simultaneous estimation of the integrated model would be preferable but
was technically not feasible. The deviation between observations and model
predictions should be minimal but a potential bias could arise which should
be evaluated at a later stage.
4.3 Data
The estimation of the model components required different data. Human
insulin (HI) was, as previously mentioned, chosen as reference insulin with a
planned evaluation of the bridging strategy based on insulin Aspart.
The integrated model should be based on data from previously conducted
24-hour MTTs. In order to test the bridging from clamp to MTT, a cross-over
HI/IAsp clamp was needed to construct a PK model and transfer function.
Furthermore, meal tolerance tests including insulin Aspart in order evaluate
the performance of the simulation.
Two Novo Nordisk trials were included that covered T2DM patients, 24-
hour MTT and treatment arms with HI and IAsp. An additional trial was
included with only a placebo arm investigating newly diagnosed T2DM pa-
tients who underwent a 24-hour MTT. The trials are described with in Table
4.1.
The resemblance between the short name for the trial BIASP and the
abbreviation for biphasic insulin Aspart (BIAsp) was unfortunate but names
were kept to maintain notation from literature. The difference in capitalised
letters should be noticed in order to distinguish trial from insulin analogue.
Meal Tolerance Tests
A total of three trials with meal tolerance tests were included for the modelling.
Two trials were cross-over trials between BHI and BIAsp treaments enabling
an evaluation of the bridging strategy within the same subjects. The third
trial was a placebo arm in a Liraglutide study i.e. no insulin treatments were
administered.
The subjects were initiated on insulin treatment until steady-state in order
to ensure that effects from previous treatments had vanished. Three standard-
ised meals were served to subjects during the 24 hours. The meals varied in
size but typically consisted of 2000 calories, which corresponds to ∼350 mmol
of glucose. Subjects were instructed to remain physical inactive as physi-
cal activity substantially affects the insulin/glucose homeostasis which would
invalidate a comparison between treatments.
In all trials, measurements of glucose, insulin and C-peptide were recorded
and profiles can be seen in Appendix D.1, D.2 and D.3 but also insulin doses,
26 4.3. Data
Name Trialname Description Subj.
ANA ANA-046 Biphasic Insulin Aspart 30 vs. Bipha-
sic Human Insulin 30 both twice daily.
A double-blind crossover study in T2DM
adults. The trial is described in an arti-
cle by McSorley et al. [2002]
13
Treatments:
BHI30 2xdaily (2 weeks)
BIAsp30 2xdaily (2 weeks)
BIASP BIASP-1074 Comparison of thrice daily ”high” vs.
”medium” premixed insulin Aspart with
respect to evening and overnight gly-
caemic control in T2DM patients. The
trial is described in an article by Ejsk-
jaer et al. [2003]
16
Treatments:
BHI30 2xdaily (1 weeks)
BIAsp70 2xdaily+BIAsp50 (4 weeks)
BIAsp70 3xdaily (4 weeks)
NN2211 NN2211-1332 Effect of Liraglutide on 24 hour glucose
and hormonal levels on T2DM patients.
The trial is described in an article by
Degn et al. [2004]
13
Treatments:
Placebo
Table 4.1: Trial description
Trial Subj Age Weight Height BMI Dia.Duration
ANA 13 64.2 (4.8) 79.3 (15.7) 1.68 (0.1) 28.0 (4.0) 13.1 (7.2)
BIASP 16 59.3 (8.1) 82.1 (8.4) 1.73 (0.1) 27.7 (2.8) 12.3 (4.9)
NN2211 13 56.4 (9.2) 91.4 (14.0) 1.71 (0.1) 31.2 (3.6) 3.0 (2.6)
Table 4.2: Summary of covariates in trials: mean (std.dev)
premix and other covariates were recorded.
The subject specific covariates measured in all three trials were: age,
height, sex, race, weight, diabetes duration, and BMI - a summary of the
covariates can be found in Table 4.2. It can be seen that the two trials ANA
and BIASP can be regarded as similar populations based on the covariates.
NN2211 has lower diabetes duration compared to the other trial populations.
At the initial stage in the modelling this was not regarded as a major issue.
The insulin and glucose profiles from the MTTs were sampled more fre-
quently around meals with ANA and BIASP having 46 observations in a profile
and NN2211 35 observations. The shortest time interval between observations
was 15 minutes and the longest time interval was one hour.
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Figure 4.3: Mealtimes in the trials
The three trials covered a period of 24 hours but were not started at the
same times during the day as shown in Figure 4.3. The displacement in time
was not a problem but simply added complexity to modelling and should be
remembered when observing plots.
The complete data basis for the meal tolerance test model was based on 42
subjects on 4 different insulin treatments and a placebo group. Three study
arms - two BHI and one placebo arm was used for estimation and three BIAsp
arms was used for evaluation. The evaluation part only covered two of the
trials but NN2211 was included to provide information on the insulin secretion
process.
Clamp
The bridging framework relies on incorporating information from a clamp
study into a simulation of a MTT. The clamp study should be used both for a
derivation of a PK model for the new analogue but also in the determination
of a transfer function.
The Novo Nordisk trial ANA-033 with results reported in Weyer et al.
[1997] is a cross-over clamp study comparing BHI30 with BIAsp30 (NM30).
The trial population consisted of 26 healthy male volunteers who received
0.3 IU/kg subcutaneous injection of premixed insulin. The mean profiles of
insulin and glucose infusion rates can be seen in Figure 4.4.
Insulin Aspart - PK Model
A pharmacokinetic model for insulin Aspart was determined as a part of a
different project whereby the PK modelling task was redundant. The data
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Figure 4.4: Mean profiles for GIR data used for transfer function
and model will be presented in the thesis but should be accredited to Andreas
Velsing Groth and Lene Alifrangis, Biomodelling, Novo Nordisk.
The estimation data were trials, using IAsp in different premix ratios. The
trials included in the PK modelling are listed in Table 4.3.
Trial Population Ratio #Subjects
ANA-046 T2 NM30 13
ANA-1199 T2 Aspart 36
BIAsp-1086 HV NM30, NM50, NM70 32
BIAsp-1318 T1 NM30, NM70 26
BIAsp-1526 T2 NM50, NM70 72
BIAsp-1746 T1 NM30, NM50, NM70 32
Table 4.3: Trials included in the Insulin Aspart PK Model
The PK model is presented in Chapter 8 where the bridging strategy is
evaluated on insulin Aspart treatment arms.
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4.4 Statistical methods
The modelling task described in this report deals with differences in struc-
tural models, different parameterisations and inclusions of additional mea-
surements. Non-linear mixed effects are used to divide the variation into
inter- and intra-subject variation according to the population model.
In this thesis the statistical model building is based on likelihood theory
which can be utilised to test nested models with likelihood ratio tests (LR-
tests). The likelihood ratio is defined as:
λ(Y) = supθ∈Ω0L(θ;Y)
supθ∈ΩL(θ;Y)
(4.1)
where L(θ,Y) is the likelihood for the model with parameter vector θ given
all data Y and the parameter space Ω0 being a subset of Ω.
The statistical setup examines whether a smaller model with parameters
as a subset of a full model describes the data equally well. The null hypothesis
is that the smaller model cannot be distinguished from the alternative - the
full model. The likelihood ratio will for equally performing models approach
1 as the likelihood of the smaller model cannot exceed the full model. When
the smaller model performs worse than the full model the likelihood ratio will
approach 0. Within the range from 0 to 1 exists a critical value c that defines
if the null hypothesis should be rejected.
A convenient asymptotic property for the statistic (−2logλ) is that the
distribution as the number of observations tend to∞ is a χ2-distribution with
degrees of freedom equal to the difference in dimensions between Ω0 and Ω
[Pawitan, 2001; Madsen, 2007]. The asymptotic properties of the statistical
test is based on the Wilk’s λ distribution.
Due to the statistic −2logλ, the objective function for an optimisation
is often defined as −2log likelihood. The Wilk’s test statistic then becomes
the difference in objective function values for the models. The critical value
for the rejection of the null hypothesis at a 5% significance level for a single
parameter is a difference greater than 3.84. The significance level of 5% was
used throughout the thesis.
The statistical model building based on the likelihood ratio test will be
used to differentiate models with different structure, processes, error models
and inter-individual effects.
Furthermore, model building will focus on physiological interpretation to
aid a simulation of unknown treatment regimens. The selection of models will
also be guided by graphical fits and comparisons with literature.
With a high level model description, estimation data, and statistical method-
ology in place, the model building could begin for the two separate models:
insulin and glucose.

CHAPTER 5
Insulin Model
The integrated model estimation was separated into sub models and this chap-
ter will focus on the insulin sub model.
The human insulin model covers absorption of synthetic human insulin,
endogenous secretion, distribution and elimination. The assay used for the
measurement of the insulin concentrations was unable to distinguish between
endogenous secreted human insulin and synthetic human insulin from injec-
tions. The origin of a single insulin molecule could thus not be traced which
complicated model building with regards to the split between secretion and
absorption.
The measured glucose concentrations were used as input into the model
to compensate for the separation into sub models. In practice, linear interpo-
lation of the glucose concentrations was used.
Frequently used covariates in model building with insulin and glucose are
baseline values. The baseline values for human insulin and glucose were ex-
tracted from the treatment arms with human insulin. The observation prior
to breakfast was used as baseline resembling regular measurement of fasting
plasma glucose.
5.1 Model Setup
The model setup was divided into absorption, secretion and disposition which
will be described in detail in the following sections.
Insulin Absorption
PK models including a description of the absorption process of injected insulin
has been modelled by Novo Nordisk but also examined and reviewed by many
others [Nucci and Cobelli, 2000].
31
32 5.1. Model Setup
Typically, the initial model structure is based on the properties of the
injected insulin e.g. physical or chemical. The chemical structure of biphasic
insulin naturally leads to a model structure for normal insulin and another
for protaminated insulin. The dissolution of protaminated insulin results in
insulin molecules identical to the normal component. It is often assumed due
to the size of the protaminated crystals that they remain in the injection depot
and do not enter systemic circulation. The transfer from depot to circulation
covers both the physical distance to veins and arteries but also passage of
membranes and tissue. The sequential absorption model structure progresses
from: protaminated insulin → normal insulin → insulin in blood; and can be
seen in Figure 5.1(a).
A different model structure assumes that the injected insulin consists of
two different components with separate pathways into circulation. The parallel
model structure potentially results in additional parameters to describe both
paths in circulation. The parallel model structure can be seen in Figure 5.1(b).
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Figure 5.1: Insulin Absorption Models
Both model structures can be extended with the inclusion of a delay com-
partment describing the transition phase between depot and plasma. A robust
estimation of a specific delay parameter requires frequent sampling during the
absorption phase which is often not the case. This challenge is often solved by
reusing absorption rate constants as delay parameters. Both versions of the
delay extension were tested either via visually inspecting profile fits, comparing
objective function values or by using likelihood ratio test when appropriate.
The intercompartmental flow is frequently modelled as first order flows.
i.e. proportional to the amount in the compartment. However, saturable or
constant flows were also tested as candidates for flow complexity.
The bioavailability of insulin was another problematic issue as no cross-over
information from intravenous to subcutaneous was available. The bioavailabil-
ity was confounded with elimination rates and volume of distribution whereby
estimation was problematic. The biphasic structure could potentially also lead
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to different bioavailabilities for the two different components. The problem of
identifiability is discussed in a later section but it was decided to assume an
overall bioavailability for human insulin and protaminated human insulin.
With regards to insulin injection, several factors add to the variability: in-
jection volume, injection site/depth and blood perfusion at the injection site
has all been shown as important factors [Nucci and Cobelli, 2000; Søeborg
et al., 2009]. If factors influenced the insulin absorption then an inter-individual
variation model would be insufficient to describe variations, but an inter-
occasion (inter-injection) variation model would be needed.
The important points in relation to the development of the insulin absorp-
tion model are:
• Serial vs. parallel absorption structural model?
Which model would best characterise the absorption profile from an
injection of biphasic insulin?
• Inclusion of delay compartment?
Should the absorption model include a delay compartment in order to
describe the transport from depot to circulation?
• Flow constants e.g. nonlinear relationships
Are first order rate constants sufficiently to describe inter-compartment
fluxes?
• Bioavailiability confounded in volume and elimination? Can
bioavailability, distribution volume, and elimination be estimated ro-
bustly without too much correlation?
• Inter-occasion variability? Should the variability model be extended
to include inter-occasion variability in order to capture differences in
absorption between injections?
The different issues cannot be tested separately from the remaining hu-
man insulin model due to inseparability of injection and secretion pathway.
The absorption model thus needs to be estimated simultaneously with insulin
secretion and insulin disposition.
Insulin Secretion
Insulin secretion occurs in the pancreas specifically in the beta cells as a feed-
back mechanism to decrease glucose concentrations. The insulin secretion
model was assumed to be glycocentric which is also a common model assump-
tion where effects of neuronal signalling and free fatty acids are disregarded
[Mari, 2002]. The secretion model should accommodate for the varying de-
gree of insulin secretion in T2DM patients where often first phase secretion
has disappeared where as others have no secretion left.
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As previously mentioned, meal ingestion will trigger insulin secretion en-
hanced by the incretin effect from intestinal hormones. In a meal tolerance
test, the incretin effect is confounded within the regular secretion and can-
not be modelled independently. This should be remembered if the integrated
model is used to simulate scenarios where no incretin effect is present.
Models able to describe insulin secretion following a glucose provocation
have been proposed and analysed in multiple articles based on different as-
sumptions and availability of data. A well known secretion model by Mari
et al. [2001, 2002a,b] is based on three components: a static, a dynamic and
a potentiation factor accounting for incretin and neuronal effects. The po-
tentiation factor has been the focus of a number of articles arguing that it
is unrelated to incretin effects [Bock et al., 2007; Cobelli et al., 2007]. A
reduced incretin effect for T2DM patients was shown in Knop et al. [2007]
adding to the arguments for a secretion model able to handle different disease
progression states.
Recent publications include free fatty acids and other non-glucose nutrients
to explain the insulin secretion [Roy and Parker, 2006; Periwal et al., 2008]
or describes the secretion via provisioning of new insulin [Overgaard et al.,
2006]. Conclusively, most approaches used to describe insulin secretion are
glycocentric i.e. glucose is used as input signal to describe insulin secretion.
The pancreas secretes insulin directly into the portal vein which passes
through the liver before reaching systemic circulation. The liver has a sub-
stantial extraction of insulin which varies over time and is often described as
non-linear. Furthermore, it is not well established which dependent variable
that best describes the hepatic extraction (HE).
Hepatic extraction of insulin has been examined in several papers. Meier
et al. [2005] states that insulin traversing the liver is the predominant de-
terminant for clearance and finds that fractional hepatic extraction is ∼80%.
Toffolo et al. [2006b] has determined hepatic extraction to be 70% in basal
state and 54% during a glucose load. Caumo et al. [2007] and Bonora et al.
[1983] both agree on a HE of ∼50%.
Pre-hepatic insulin secretion is practically immeasurable in-vivo and can
usually only be quantified via C-peptide. The modelling of insulin secretion
should either describe pre-hepatic secretion and account for HE or focus on
describing the post-hepatic insulin delivery into systemic circulation.
• Insulin Secretion
Insulin secretion is modelled and coupled with hepatic extraction to
determine the insulin delivery. The model setup allows for inclusion of
C-peptide measurements to quantify pre-hepatic secretion rates. The
drawback is that a model for HE is required and it isn’t well described.
Furthermore, the model relies on PK parameters extrapolated from Van
Cauter [Cauter et al., 1992] to describe C-peptide kinetics.
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• Insulin Delivery
Insulin Delivery to systemic circulation is modelled directly in an em-
pirical manner bypassing the effect of the hepatic extraction. The first
pass effect is thus lumped into the feedback parameters from the glucose
influence.
The advantage of the insulin secretion model is that C-peptide concen-
trations can be included into the model. C-peptide is a by-product from the
secretion of insulin that comes from the split of proinsulin into insulin and
C-peptide. Insulin is thus secreted in equimolar amounts as C-peptide. C-
peptide has a longer half life than insulin, does not suffer from first pass effect,
and well behaved kinetics, all in all making it a reliable marker for pre-hepatic
secretion rates. The inclusion of C-peptide measurements implies the inclusion
of a PK model for C-peptide. A population model with covariates: gender and
age was published by Cauter et al. [1992] and constitutes the golden standard
for C-peptide modelling.
The alternative approach is an empirical focus on insulin concentrations.
From a simplistic point of view only post-hepatic insulin delivery rate in
plasma is required to describe insulin changes in plasma. The insulin de-
livery model aims at directly linking glucose observations with insulin plasma
appearance. The insulin delivery model thus lumps secretion and hepatic
extraction into a single model. The physiological interpretation of the param-
eters is diminished but a simpler model is achieved.
Both model types were tested during model building simultaneously with
the insulin disposition which is the focus for the next section. To recap the
important points on insulin secretion modelling
• Glycocentric secretion model
Insulin secretion was assumed to be driven by glucose signals in a PID
setting (Proportional, Integral and Derivative).
• Insulin secretion / Insulin delivery
How should the insulin secretion be included in the model either via a
model for pre-hepatic secretion coupled with hepatic extraction or via
an empirical description of post-hepatic insulin delivery into plasma?
• Hepatic extraction - functional form, dependent variable
If insulin secretion is modelled via pre-hepatic secretion - What func-
tional relationship that best describes HE and based on which dependent
variables?
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Insulin Disposition
The disposition model for insulin has influx from injected insulin and en-
dogenous insulin secretion which in the case of human insulin have identical
disposition.
In literature a range of different insulin kinetic models have been suggested,
structurally ranging from one to three compartments. Castillo et al. [1994]
analysed both IVGTT- and OGTT-experiments with a three compartment
structure and two elimination pathways and found half lives for insulin of 2.4
min and 130 min. A three compartment structure is supported by Sherwin
et al. [1974] whereas a two compartment structure was used to mimic liver
and periphery by Man et al. [2007b].
A review article by Nucci and Cobelli [2000] compares several models for
subcutaneous injected insulin, several of them having a one compartment
structure for distribution. The one compartment structure is also supported
by Silber et al. [2007] in a 24-hour integrated model.
The basis for the insulin distribution model was a one compartment struc-
ture with first order elimination.
The focus on simplicity originates in identifiability problems for parame-
ters. The process setup with multiple inseparable input pathways, distribution
and elimination unfortunately results in identifiability issues. The insepara-
bility of insulin origins spills into estimated parameters causing parameters to
become highly correlated. Especially, parameters influencing the scaling of in-
sulin concentrations such as bioavailability, volume of distribution, elimination
rate constant, and endogenous secretion. Solutions stabilising the estimation
could be introduction of priors which could be used in a Bayesian estimation
scheme or by fixing parameter values. The Bayesian estimation would have
been preferable but not easy achievable in NONMEM V which resulted in a
fixation approach being applied.
5.2 Model Building
This section will present the insulin modelling results and highlight important
choices that were made during the modelling process. The modelling was not a
linear sequence of models being tested. Challenges and ideas induced a parallel
working environment where different models were tested simultaneously. The
run times for parameter estimation in NONMEM lasted from minutes to hours
which also contributed significantly to parallel tracks of model classes.
Insulin Disposition
Initially, the model building was simplified by determining the pre-hepatic se-
cretion rate via deconvolution based on C-peptide measurements and the Van
Cauter model [Cauter et al., 1992]. The deconvolved pre-hepatic secretion
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rates were used directly as inflow into the insulin disposition model reduc-
ing the computational complexity. A similar approach was also used by Mari
et al. [2001] however their approach was refined by replacing the classic de-
convolution of C-peptide with deconvolution based on stochastic differential
equations as shown in Paper B.
The deconvolved pre-hepatic insulin secretion rates were adjusted for changes
in distribution volume between C-peptide and insulin. The different struc-
tural setups for absorption (sequential and parallel) were combined with the
one compartment disposition model and different HE models. One structural
model can be seen in Figure 5.2. The initial models had severe identifiability
problems with unphysiological estimates of distribution volume and elimina-
tion.
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Figure 5.2: Insulin disposition model
The model type found in Figure 5.2 is in correspondence with the model
structure previously determined at Novo Nordisk but the inseparability of in-
puts resulted in correlated parameters due to counteracting effects. Literature
values were used as the next step in order to fix parameters.
The next generation of models had a fixed volume for insulin of 0.12 L/kg
which is supported by Hovorka et al. [2004]. The distribution volume for C-
peptide was determined using body surface area as described in Cauter et al.
[1992]. The insulin absorption model was still sequential.
The model for hepatic extraction was tested in different functional forms:
constant, linear or saturable with different dependent variables: insulin secre-
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tion rate or insulin concentration - both variables were also tested in log scale.
The hepatic extraction models were tested in the model shown in Figure 5.2.
The shown model was found to be the optimal insulin model. It reused the
fast absorption constant for a delay compartment and had a linear hepatic ex-
traction with insulin secretion rate as dependent variable. The inter-subject
variability was explained with random effects on parameters Ke, Kaf and F
- furthermore extended with inter-occasion variability on the Kas parameter.
The hepatic extraction was parameterised as:
HE = 0.55 + α(ISR− 100) HE ∈ [0; 1] (5.1)
where LVPT = 1 − HE. The values 0.55 and 100 were selected as a baseline
hepatic extraction of 55% at 100 pM/min. α was estimated but constrained
to be negative such that HE decreases as ISR increases.
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Figure 5.3: Mean insulin fits pr. group
In Figure 5.3 the mean profiles of insulin observations and individual pre-
dictions are plotted per trial. The contribution from injected insulin is shown
with the green line.
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The general fit to observations for ANA looked good but dinner peak
was under predicted. The fit for BIASP was worse with problems relating
to initial conditions and a slight overestimation of the breakfast and lunch
peak. For NN2211, peaks and troughs are both correspondingly under- and
over-estimated resembling an average fit for the level.
The seemingly non-smooth contribution from injected insulin was due to
the modelling using actual time points for observations as opposed to nominal
time points. The initial condition was a steady state condition for based on
a replica of the last two insulin doses inserted the day prior to the MTT in
order to account for accumulation.
Insulin Secretion
With insulin absorption, disposition and hepatic extraction in place, the mod-
elling of insulin secretion was initiated to replace the deconvolved pre-hepatic
secretion rates with a model able to describe pre-hepatic secretion and thereby
C-peptide measurements.
The C-peptide model by Cauter et al. [1992] was used as a dynamic model
with an input driven by glucose concentrations. The rate parameters in the
model were determined using the covariate age according to the article. The
Van Cauter subject population was younger with larger BMI compared to the
trial populations. This could potentially bias the results as the Van Cauter
parameter relationship is beyond its original scope.
The insulin secretion rate model was tested with different dependent vari-
ables: glucose, delayed glucose and a signal from the derivative of the glucose
concentrations. The derivative of the glucose signal had to be derived from
data pre-modelling whereas the delay parameter in the integral glucose sig-
nal was estimated simultaneously. Besides the glucose dependent terms the
secretion rate model also included a baseline secretion.
The statistical model building showed that only the proportional term
was significant. The delay parameter was estimated very low, which indicated
a collapse of the delayed part towards the proportional part. The individual
plots showed that the high secretion peaks were not captured, which intuitively
would be improved by including a derivative term but the improvement was
not statistically significant. The sampling period of minimum 15 minutes could
conceal the effect of the derivative in the proportional term as the glucose
concentration increases within 15 minutes of meal ingestion.
The fit for the insulin secretion model to C-peptide concentrations can
be seen in Figure 5.4. The mean fits were good for both ANA and BIASP
whereas the fit for NN2211 was poor for both lunch and dinner.
The C-peptide concentrations added information on the pre-hepatic insulin
secretion rates based on the Van Cauter model at the cost of the introduction
of hepatic extraction in the insulin model. The model was combined with a
glucose model for an evaluation of the integrated model for human insulin.
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Figure 5.4: Mean C-peptide fits pr. trial
Model Evaluation
The insulin model and a glucose model (described in Chapter 6) were combined
and used to simulate different scenarios in order to evaluate performance. The
integrated model was used to simulate an insulin tolerance test and a clamp
experiment.
A concern was that insulin secretion included incretin effects that would
not occur in clamp scenarios. As a result, the scenarios were simulated know-
ing that the insulin secretion potentially could be too large with subsequently
enlarged glucose elimination.
The comparison for the insulin tolerance test was made with the article
by Inchiostro [2005] where 247 T2DM patients were studied. Glucose concen-
trations were measured at -15 and -1 min and 3, 6, 9, 12, and 15 min after an
intravenous bolus injection of insulin (0.1 IU/kg). KITT was calculated as the
half life of glucose. The result of the simulations can be seen in Table 5.5(a).
The clamp evaluation was a comparison with a Novo Nordisk conducted
trial (NN304-1439) where an iso-glycemic clamp with three dose levels of sub-
cutaneous injected NPH insulin (0.3, 0.6 and 1.2 IU/kg) had been conducted
in T2DM patients. The AUCs of the glucose infusion rates were compared to
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trial results which can be seen in Figure 5.5(b).
KITT %/min
Inchiostro [2005] 2.88 ± 0.99
ANA 1.19 ± 0.81
BIASP 2.15 ± 3.03
NN2211 0.81 ± 0.82
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Figure 5.5: Model Evaluation
The insulin tolerance test (Table 5.5(a)) shows that the simulated decrease
in glucose for all three groups are lower than reported in literature.
For the clamp simulation, both ANA and BIASP have a lower GIR AUC
compared to the reference trial, however NN2211 had a larger response to
insulin compared to both ANA and BIASP but also the reference trial.
The result of the model evaluation as seen in Figure 5.5 was that the model
was not sufficiently insulin sensitive in the insulin tolerance test and the clamp
experiment. With regards to insulin secretion, it should be remembered that
incretin effect was confounded within the estimation such that the secretion
during a clamp experiment should be too high leading to a higher insulin
action. The conclusion was to change the glucose/insulin action model into a
more insulin sensitive version which will be described in Section 6.2.
With regards to the insulin model it was decided to switch to an insulin
delivery model. The decision was based on insulin fits, uncertainty regarding
extrapolations in the C-peptide model coupled with uncertainty in hepatic
extraction. A switch to insulin delivery type model would simplify the model
structure.
Furthermore, NN2211 had at this point also caused several problems in
the glucose model estimation and the result in Figure 5.5(b) added to the
belief that the NN2211 population was too different compared to other T2DM
patients. The differences in demographics as described in Table 4.2 page 26
were more influential than initially anticipated. Consequently, it was decided
to exclude NN2211 as a population group from the modelling.
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5.3 Insulin Delivery
The parameters in the insulin model were re-estimated with the insulin de-
livery rate (IDR) component and the corresponding model structure that can
be seen in Figure 5.6.
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Figure 5.6: Insulin Model structure with Insulin Delivery Rate
The glucose effects were tested in the IDR model and only the proportional
effect of glucose concentration and a basal delivery rate were statistically sig-
nificant. The direct effect of glucose was modelled as the glucose concentration
above baseline as the insulin delivery at basal glucose is the basal delivery
rate. The parameters describing the insulin delivery rates were determined
with inter-subject variation, which was tested significant.
The updated insulin model was simpler with glucose observations linked
into insulin delivery rate, which unfortunately rendered C-peptide observa-
tions redundant. An interesting challenge would be how to include C-peptide
observations in an insulin delivery type of model, but this analysis was not
pursued.
The full range of models that could be combined with different structures,
included processes and inter-individual variations were not all tested. The
tested models were selected based on prior knowledge and experience gained
through the modelling.
The final model was a compromise of identifiability obtained by use of lit-
erature values for volume of distribution VI but also insulin elimination (Ke)
which was fixed to 0.075 min−1. The model included both inter-individual
variation on secretion parameters (Alfa and IDRB) and bioavailability (F ).
Inter-occasion variation was added to absorption parameters (Kas and Kaf ).
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The model structure can be interpreted from a physiological viewpoint and
resembled previous models within insulin modelling. The model fits are seen
in Figure 5.7. The mean profiles fitted observations quite well with the in-
sulin delivery model. The BIASP pre-breakfast level was overestimated but
remaining peaks and troughs was fitted nicely.
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Figure 5.7: Mean fits with Insulin Delivery Rate
The plot clearly shows that the insulin fits are much better compared to
the previous insulin secretion model type (Figure 5.3)but there was a con-
cern that the insulin basal delivery rate was estimated too high as the glucose
dependent insulin response was low. However, due to inseparability of input
pathways this could not be investigated nor rejected on the current fit.
The next step was to construct a glucose model that could be combined
with the human insulin model in order to create an integrated model for human
insulin. The glucose model is the topic for the next chapter where both model
building and selection is covered.

CHAPTER 6
Glucose Models
The separate estimation of the human insulin model was covered in the last
chapter. This chapter will describe the model building of the glucose model
using insulin concentrations as input.
Glucose absorption, disposition and elimination have been modelled in
a range of different models. The most well known model is the Bergman
minimal model [Bergman et al., 1979] which is often described as a balance
between data availability, physiological knowledge and mathematical flexibil-
ity [Bergman and Lovejoy, 1997]. Reservations with regards to the minimal
model concerns that it was originally based on IVGTT data, but has since
been adapted to MTT and OGTT [Man et al., 2004, 2002], the later denoted
as the oral minimal model.
An alternative model was proposed by Hovorka et al. [2002]. It includes
three insulin actions on respectively inter-compartmental distribution, glucose
disposal and endogenous glucose production (EGP).
In the period of the PhD programme several articles on models for insulin
and glucose have been published by other groups. An IVGTT model was pro-
posed by Silber et al. [2007]. This model is based on labelled glucose, which
enables more detailed processes to be identified. A 24-hour model also based
on labelled glucose data was presented by Man et al. [2007b,a]. It was esti-
mated on single meal data, and subsequently extended into a 24-hour model,
which was validated on 24-hour MTT data. Hovorka et al. [2007] used a two
compartment structure to analyse tracer studies. The use of labelled glucose
facilitates quantification of processes normally in-observable using cold1 data.
Specifically, a separation of glucose gut absorption and endogenous glucose
production (EGP) is possible when tracer techniques are used.
1The expression cold data refers to standard observations of glucose whereas hot data
refers to the use of radioactive tracers or stable isotopes of glucose
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The oral minimal model [Man et al., 2002] will be used as a basis for the
model building. The current model includes a meal function that describes
glucose appearance following ingestion of meals.
dG
dt
=Up − SG · (G−Gb)− SI ·X ·G (6.1)
dX
dt
=p2 · ((I − Ib)−X) (6.2)
where Up is the meal function and SG is the glucose effectiveness, which de-
scribes glucose effects on its own disposal. SI is the insulin sensitivity that
describes insulin’s effect on glucose disposal. X is the insulin action, which
physiologically is often interpreted as interstitial insulin concentrations with
a delay parameter p2.
In periods with high glucose concentrations, the liver converts glucose into
glycogen for storage and in periods with low glucose concentrations, glucogen
is converted back into glucose. This dual role of the liver can usually be
neglected in shorter trials as such experiments do not impose both roles. In a
MTT covering 24-hours the liver will assume both roles, but often the model
assumption is that EGP is constant.
6.1 Meal Function
The expression ”meal function” refers to a mathematical function that de-
scribes the glucose rate of appearance following a meal. The rate absorption
profile is influenced by many factors e.g. meal composition, previous meals
and amount of liquid.
Lehmann and Deutsch [1992] published a physiological model of insulin
and glucose that incorporated glucose absorption. The model is based on an
empirical description of the gastric emptying rate. Recently, a mixed meal
model was proposed by Man et al. [2006a,c,b] which divides the meal into
a solid and a liquid state in the stomach followed by an intestine state. The
model includes a non-linearity in the gastric emptying rate dependent on total
amount of glucose in the stomach. A model including the mixed meal function
was published in [Man et al., 2007b,a] after the current modelling work and
is mentioned for a more complete overview.
The different approaches to glucose rate of appearance seem different in
form and physiological interpretation but the resulting glucose absorption pro-
files are similar in shape.
The meal function parameterisation used in this thesis is described in
[Hansen, 2004]. It is a sum of two exponentials where an upper limit for the
area under curve (AUC) in the meal function is ingested glucose as either
recorded during the trial or specified in the protocol. The meal function can
be simplified by assuming identical time constants.
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Up = 2 ·MAp ·MKp · e−MKp·t(1− e−MKp·t) (6.3)
The product (2 ·MAp ·MKp) is used to normalise the AUC based on an
upper bound of ingested glucose (MAp). MKp is a rate parameter and Up is
the rate of appearance of glucose from meals. p denotes the different meals
during 24 hours (p = 1, 2, 3).
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Figure 6.1: Schematic Meal Function
The glucose model with meal function suffered from identifiability issues.
The contribution in plasma glucose from meal could not be separated from
EGP. Furthermore, glucose elimination and meal function have opposing ef-
fects. The process of selecting candidates for parameters that could stabilise
estimation and the model building in general is the focus point for the next
section.
6.2 Model Building
The model building had parallel tracks and choices were influenced from dif-
ferent tracks but also the insulin model building. Combined parameter esti-
mation for trials proved to be unstable and was quickly split into pr. trial
estimation, which increased stability.
The glucose models were tested in two structural versions: one or two
compartments. The possibility to fix parameters to literature values was also
explored. Random effects were included for inter-individual variation describ-
ing the glucose kinetics.
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Regarding the meal function, different parameterisations were tested with
random effects on rate constants and/or meal sizes. The most robust solution
was a trial specific meal function which fitted nicely into the bridging strategy.
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Figure 6.2: Glucose Models
As a starting point for the modelling, the glucose volume of distribution
was fixed to 17 litres advised from Morten Colding-Jørgensen and Roman
Hovorka. The distribution volume for glucose was an object for investigation.
In Table 6.1, glucose volumes from different publications are listed. The table
shows that often the volume of distribution is weight normalised. A volume
of 17 litres will for an 80 kg individual correspond to 2.13 dl/kg, which is in
agreement with reported values from cold data and T2DM.
Publication Glucose Vol Comment
Steele et al. [1956] 1.69 dl/kg Dilution, Dogs,
see [Finegood and Tzur, 1996]
Radziuk and Pye [2002] 18% of weight Tracer, T2DM
Finegood and Tzur [1996] 2.50 dl/kg Mean literature value, T1DM
Man et al. [2002] 1.7 dl/kg Prior for healthy
Sunehag et al. [2009] 2.40 dl/kg Prior for T2DM
Hovorka et al. [2002] 1.60 dl/kg * Healthy males, hot IVGTT
Man et al. [2007b] 1.49 dl/kg * Healthy+T2DM, hot MTT
Silber et al. [2007] 9.33 liter * Healthy+T2DM, hot IVGTT
* Estimate for central compartment in two compartment models
Table 6.1: Glucose volume of distribution
Parameter estimation in two compartment structures had inter-compartmental
rate constants fixed, as they could not be estimated from cold data. The rate
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parameters were fixed to k12 = 0.05 and k21 = 0.07. This is in accordance with
literature values shown in Table 6.2 and also used in Hovorka et al. [2007]. The
delay for insulin action p2 was fixed to 0.03 min
−1 in some models candidates.
Article Population #Subj k12 k21 Reference
Silber Healthy+T2D 72 0.047 0.052 [Silber et al., 2007, p.1166]
Krudys Healthy 10 0.068 0.110 [Krudys et al., 2005, p.1043]
Hovorka Healthy 6 0.065 [Hovorka et al., 2002, p.998]
Hovorka Healthy 6 0.079 0.121 [Hovorka et al., 2002, p.1001]
Vicini Healthy 14 0.070 0.080 [Vicini et al., 1997, p.1028]
Table 6.2: Literature values for glucose inter-compartmental rate constants
In literature different values for p2 and SG have been published and fixed
parameters are in range with reported values in Hovorka et al. [2002] and
Man et al. [2004]. Many articles have discussed the overestimation of the SG
parameter in the minimal model [Cobelli et al., 1998; Caumo et al., 1999;
Vicini et al., 1999] as a result of modelling. The SG parameter was set to
0.0055 min−1, which was determined as a representative value from the pub-
lications using labelled glucose to determine SG (see Table 6.3).
Article Population #Subj Comp SG
Avogaro et al. [1996] T2D 7 1 0.0053
Hovorka et al. [1998] Healthy 10 1 0.0089
Vicini et al. [1997] Healthy 14 2 0.0038
Table 6.3: Litterature values for SG
The performance of the glucose models were evaluated on fit to observa-
tions, objective function values (OFV) but also evaluated on their correspon-
dence with results from literature.
Model Selection
The initial models included random effects on p2, SI and SG but also tested
random effects on the trial specific meal parameters.
Similar to the insulin model building, the range of potential models was
substantial and the full combinational tree of structural models, random ef-
fects and parameterisations was not traversed, but relevant groups were in-
vestigated. The models were compared on general fit to observations, OFV,
physiological interpretation and correspondence with literature.
The initial models were mainly evaluated on their ability to capture meal
sizes in correspondence with protocols. The main problem was increased flex-
ibility of the meal function obtained with random effects decreased the effect
of insulin (SI). It was hypothesised that the meal function captured all the
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variation in the observations which motivated a shift to a trial specific meal
function.
The first version of the glucose model was a one compartment structure
with random effects on p2, SI and SG and a trial specific meal function. The
model was combined with the insulin model (pre-hepatic insulin secretion)
and used to simulate scenarios (euglycemic clamp and insulin tolerance test,
see Chapter 5.2 page 36). As previously mentioned in the insulin chapter,
the analysis led to a series of conclusions. The main conclusion was that the
combined model was not insulin sensitive enough and led to a changed insulin
appearance model, which disregarded C-peptide measurements, an exclusion
of the NN2211 population from estimation data and a new glucose model
building with the focus on a more insulin sensitive model.
A range of potential models were re-investigated, specifically analysing the
fraction between insulin dependent elimination (IDE) and total elimination2.
The models were compared to the model in the evaluation to investigate if the
elimination fraction had increased towards a more insulin sensitive model.
According to literature, glucose elimination via non-insulin meditated path-
ways should be ∼50% for normal subjects and ∼83% in obese insulin resistant
individuals [Best et al., 1996]. Baron et al. [1985] state that the fraction should
be 71% for T2DM and 75% for normal subjects.
The fractions of insulin mediated glucose elimination for different model
candidates can be seen in Table E.1. The articles just mentioned report the
non-insulin mediated elimination but the model derived fractions reported in
the table are insulin dependent elimination fractions. Furthermore, literature
values are based on clamp experiments and described as being representative
for a post-absorptive state, which differs from a MTT model setup that in-
cludes all phases over 24 hours. Despite an increased divergence compared to
literature values, it was decided to opt for a more insulin sensitive model.
The model selection was also based on estimates for glucose effectiveness
(GE ) found in literature. GE is the effect of glucose per se to stimulate its
own uptake and inhibit hepatic glucose production. A number of publications
were selected [Best et al., 1981, 1996; Prato et al., 1997; Hawkins et al., 2002],
all described hyperglycaemic clamp experiments from which GE indexes could
be derived. The glucose effectiveness is defined as shown in Equation (6.4).
The SG parameter is often denoted glucose effectiveness as it describes the
glucose effectiveness in the minimal model but the parameter only explains a
part of the physiological effect.
GE =
δRD
δG
∣∣∣
SS
=
δ(RU − EGP )
δG
∣∣∣
SS
(6.4)
where RD is the total glucose disposal. RU is glucose uptake and EGP is
endogenous glucose production.
2Total elimination = IDE + IIE (Insulin In-dependent Elimination)
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The GE indexes from literature cannot be directly compared to model
estimates due to differences in insulin baselines. The literature indexes origi-
nate from different physiological scenarios, typically clamp experiments with
different insulin levels and had to be adjusted accordingly using Equation
(6.5).
GE = (SG+ SI ∗ (IPub − Ib)) ∗ VG (6.5)
where IPub is the mean insulin level in the publication and Ib is the individual
basal insulin level.
Table E.1 page 216 summarises the GE for model candidates, which should
be compared to the three publications in the bottom of the table. The com-
parison shows that the models for ANA and BIASP have GE in the same
range as the publications.
The glucose model selection resulted in a glucose model with a fixed SG as
a compromise of OFV, GE estimates and insulin dependent elimination. The
parameterisation included random effects on SI and p2 and a meal function
that was trial specific.
Different error models have been tested and initially proportional was used,
but due to stability a switch was made to an additive error model. The model
fits can be seen in Figure 6.3. The fits can be seen to be close to observations
but with some artefacts from the calculation of the mean profile.
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Figure 6.3: Fits from Glucose Model
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The next step was to combine the final models for insulin and glucose into
an integrated model and verify that the data used for estimation could still
be predicted. Furthermore, a series of evaluation scenarios was simulated and
compared to literature. The overall qualification of the integrated model will
be the subject of the next chapter.
CHAPTER 7
Integrated Model Evaluation
The integrated model for insulin and glucose was created by combining the
two sub models that were previously described. Both models were estimated
using measured concentrations as input to model either glucose driven insulin
secretion or insulin driven glucose elimination. This chapter will evaluate the
integrated model both on estimation data but also in a series of scenarios
which can be compared to literature.
The scenarios were also used during model building and consist of a eug-
lycemic clamp and an insulin tolerance test simulation. A sensitivity analysis
on the insulin doses was performed as an additional scenario that should be
evaluated subjectively.
The scenarios that were used to evaluate the performance of the integrated
model were:
• Prediction of estimation data
The integrated model was used to predict estimation data to investigate
potential bias from the separate estimation.
• Euglycemic Clamp
A clamp scenario was simulated with three different dose levels and
resulting AUCs were compared to a similar trial.
• Insulin Tolerance Test
An ITT was simulated and results were compared to results from a
reported study.
• Sensitivity Analysis on insulin doses
Insulin doses were altered (doubled and halved) and the correspond-
ing glucose profiles were analysed. The analysis was subjective as no
reference was available.
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7.1 Model Description
Prior to evaluating the integrated model in different scenarios, the model will
first be described in detail and estimated parameters be presented.
The model consisted of a system of ordinary differential equations that
described both insulin and glucose dynamics. The model can be seen in
schematic form in Figure 7.1 and equations can be seen in the following equa-
tions (7.3)-(7.11). The estimated parameters are shown in tables 7.1 - 7.3.
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Figure 7.1: Simulation Model
Some parameters were not estimated directly due to constraints. F was
estimated using a logit transform to ensure values within [0; 1]. Parameters
Kas and Kaf were estimated using a relationship that guarantied that Kaf
was faster than Kas also at the individual level shown in equations (7.1)-(7.1).
Kas,breakfast = Kas · eηas,breakfast (7.1)
Kaf,breakfast = Kas,breakfast +Kaf · eηaf,breakfast (7.2)
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Insulin Model
dISlow
dt
= (1−Ratio) · F ·Dose−Kas · ISlow (7.3)
dIFast
dt
= Ratio · F ·Dose+Kas · ISlow −Kaf · IFast (7.4)
dIDelay
dt
= Kaf · (IFast − IDelay) (7.5)
dICentral
dt
= (α(Gluconc −Gb) + IDRB) +Kaf · IDelay −Ke · ICentral (7.6)
Insconc =
ICentral
VIns
· (1 + I) (7.7)
Glucose Model
dX
dt
= p2 · (Insconc − Ib)− p2 ·X (7.8)
Up = 2 ·MAp ·MKp · e−MKp·tp(1− e−MKp·tp) p = 1, 2, 3 (7.9)
dG
dt
= U/VG + SG ·Gb − SG ·G− SI ·X ·G (7.10)
Gluconc = G+ G (7.11)
ANA BIASP
Name Var Type Value Variance Value Variance
F* IIV,IOV 0.476 2.83 0.412 1.94
Kas IIV,IOV 3.27E-03 0.171 2.47E-03 0.139
Kaf IIV,IOV 9.15E-03 0.473 1.03E-02 0.301
α IIV 7.09E-05 0.658 1.73E-05 3.17
IDRB IIV 5.74E-04 0.454 7.29E-04 1.56
Ke FIX 7.50E-02 - 7.50E-02 -
VI FIX 0.12 - 0.12 -
I - - 2.42E-02 - 2.15E-02
* logit transformed [0;1]
Table 7.1: Estimated Insulin Model Parameters
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ANA BIASP
Name Var Type Value Variance Value Variance
P2 IIV 3.60E-02 1.06 1.61E-02 1.45
SI IIV 1.29E-05 0.78 1.92E-05 1.13
SG FIX 5.50E-03 - 5.50E-03 -
VG FIX 17 - 17 -
G - - 2.61 - 3.64
Table 7.2: Estimated Glucose Model Parameters
ANA BIASP
Breakfast Lunch Dinner Breakfast Lunch Dinner
MA 385 304 261 346 266 263
MK 1.55E-02 1.23E-02 1.39E-02 1.59E-02 1.24E-02 1.18E-02
Table 7.3: Estimated Meal function parameters
Prediction of Estimation Data
The potential bias from the separate estimation was assessed by predicting
the estimation data with the integrated model.
The simulation with the integrated model used insulin doses and weight
covariates from data and a parameter set for each subject that described the
insulin and glucose models. The trial MTT was as a steady state treatment
experiment i.e. after several days of treatment. The simulation replicated
this by simulating several days of treatment in order to obtain a steady state
situation but also to eliminate artefacts from initial conditions.
In Figure 7.2, the simulated insulin and glucose are compared for groups
ANA and BIASP. The full line is the mean simulation and the points are mean
observations. For ANA both insulin and glucose fits are generally good with
the largest misfit at dinner peak in the insulin profile. The largest misfit for
BIASP is seen in the overnight period in the insulin concentrations.
The increasing insulin prediction around lunch time indicates that insulin
secretion is present as the exogenous insulin is decreasing in this period. How-
ever, the contribution from the basal delivery still seemed high compared to
the glucose driven delivery.
The conclusion for the prediction of the estimation data was that both
insulin and glucose were well described by the integrated model i.e. that no
bias had been introduced by the separate estimation.
Isoglycemic Clamps
Glucose clamps are used in clinical trials to assess safety and provides valuable
information on the insulin delay and action [Heinemann, 2004]. This evalu-
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Figure 7.2: Prediction of Estimation Data
ation scenario was also used during the model building and it simulated a
glucose clamp identical to a study conducted at Novo Nordisk (NN304-1439).
Patients were clamped at 7.2 mmol/l glucose and had three different insulin
dose levels (NPH 0.3, 0.6 and 1.2 IU/kg). The glucose infusion rate (GIR)
profiles from NN304 are shown stratified by ethnicity (Blacks, Hispanics and
Whites) in Figure 7.3.
The simulations are compared to the trial results by GIRAUC , GIRTmax
and GIRmax. The measured GIR profiles have a flat plateau in the insulin
action profile where an estimate of GIRTmax is uncertain for which reason the
comparison was only visual. The GIRAUC was calculated from [0; 16] hours
after injection for all dose levels. The GIRAUCs from simulations were then
subsequently compared to trial reported values.
The simulated GIR profiles are shown in Figure 7.4. The individual profiles
have been adjusted to an intercept identical to the mean NN304 starting point
(0.5 mg/kg/min). The adjustment was needed as the simulated GIR profiles
could become negative due to a model artefact from glucose baseline values.
The GIR increase, needed to counteract the effect of injected insulin, can
be seen to differ in shape for simulations and trial groups. The GIRmax was
in the correct range but the peak is more pronounced in the simulations than
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Figure 7.3: GIR profiles from NN304-1439 (ICTR p. 50)
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Figure 7.4: Simulated GIR profiles
compared to NN304 trial profiles.
A comparison of GIRTmax was difficult but it can be seen that the delay
before plateau compares to GIRTmax for the simulations. The tails of the
simulated profiles can be seen to return to a near baseline value whereas the
reported profiles remain on the plateau.
The GIRAUCs were calculated and compared to trial AUCs in Figure 7.5.
The slope of the lines indicated that the increases in GIR response for in-
creasing dose were equal for simulations and reported AUCs. The absolute
response is lower for the simulated values which indicated low insulin sensi-
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Figure 7.5: AUC of the GIR Profiles
tivity. However, the scaling mentioned to remedy the artefacts from glucose
baselines have a great influence on calculated AUC.
The conclusion was that the clamp scenario revealed discrenpancies in
relation to shape of GIR profiles and also the comparison of GIRAUC was not
on par.
Insulin Tolerance Test
Another scenario used in the evaluation was an insulin tolerance test (ITT).
It was also used during model building (Section 5.2) and was repeated here
for the evaluation of the integrated model.
The ITT measures the rate of decrease in glucose after an IV insulin bolus
dose. Inchiostro [2005] reports the results of an ITT conducted where pa-
tients after an overnight fast were dosed IV with 0.1 IU/kg insulin. Venous
blood samples were collected at -15,-1,3, 6, 9, 12 and 15 min and the glucose
concentrations were determined. The index KITT is the elimination rate con-
stant from a first order decline in the time period [3, 15]. The ITT setup is
illustrated in Figure 7.6 where the red line is the first order decline.
The article by Inchiostro [2005] analyses a group of newly diagnosed T2DM
patients. The comparison between the groups should be weighted with the
fact that ANA and BIASP consist of patients who were not characterised as
newly diagnosed. The reported KITT for the ANA and BIASP groups are
seen in Figure 7.7. It can be seen that the calculated KITT are closer to the
reported values than during model building.
Physiologically, it means that insulin driven glucose disposal in the model
is not as fast as reported in literature i.e. the glucose disposal is not as sen-
sitive to insulin. Furthermore, the uncertainty (standard deviation) is large
indicating a very inhomogeneous group of parameter values. A hypothesis for
the large variation could be the influence of glucose baselines which compli-
cated the analysis.
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Figure 7.7: Group mean ± sd
of KITT
The conclusion was that the ITT did not falsify the integrated model but
were also not in complete correspondence.
Sensitivity Analysis
The evaluation also included a ”what-if” scenario where insulin doses were
altered. The insulin doses were halved and doubled in order to evaluate how
the integrated model responded to a substantial change in dosed insulin. The
subjects in ANA and BIASP received ∼ 50 IU/day, which from a titration
viewpoint confirms that the populations were insulin resistant [Hirsch et al.,
2005].
The results of the sensitivity analysis could not be compared to literature
but only be evaluated on a subjective basis. Intuitively, the glucose concentra-
tions should drop dramatically if dose was doubled. Normally, hypoglycaemic
episodes could be expected but as the model was not estimated in the low
glucose range or had processes included that describes hypoglycaemia, it was
unclear how the model would perform.
Figure 7.8 shows the profiles with changed insulin doses. Both alterations
of dose induced a change to the glucose profile but none of them was as
pronounced as expected. This subjective measure also supports the belief
that the integrated model was insulin insensitive.
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Figure 7.8: Insulin dose sensitivity analysis with the integrated model
7.2 Human Insulin Evaluation Round-Up
The integrated model was evaluated in scenarios which aimed at different
aspects of the insulin/glucose system.
The prediction of estimation data evaluated the separate estimation scheme
and assessed overall performance. The clamp scenario targeted the insulin ab-
sorption and action part of the integrated model. The insulin action was also
the focus of the insulin tolerance test scenario whereas the sensitivity anal-
ysis of insulin doses was a subjective scenario, which evaluated the entire
integrated model.
The evaluation scenarios were not exclusively confirmatory due to simu-
lation outcomes that were not completely on par with literature. In general,
the deviations were considered minor in comparison to the variation in pro-
files/study population etc. A model insulin sensitivity issue was identified
during model development and triggered a shift in model structure and esti-
mation data. The lack of insulin sensitivity was unfortunately still present in
the evaluation scenarios which were also supported by the sensitivity analysis.
Additionally, glucose effectiveness was used to evaluate/compare potential
models during glucose model building in which model derived GEs were in
range with reported values.
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The integrated model was able to predict the estimation data nicely, so for
descriptive purposes the integrated model performs adequately. In relation to
external evaluation scenarios, the integrated model had issues, but was still
reasonably similar to literature. It was decided to proceed in the project to
an integration of insulin Aspart in a bridging setup.
CHAPTER 8
Bridging Strategy Evaluation
The overall goal with the project is a bridging of a new insulin analogue only
investigated in clamps into an integrated model in order to simulate 24-hour
glucose profiles from meal tolerance tests. The integrated model for human
insulin will form the basis which in this chapter will be used for a bridging
of insulin Aspart (IAsp) by which the bridging strategy performance can be
assessed.
The premises of the bridging strategy imply that information on insulin
Aspart should originate from clamp experiments. This requirement was ful-
filled with only minor deviations.
The original estimation data for the integrated model was based on human
insulin treatment arms with corresponding cross-over treatment arms with
insulin Aspart. The cross-over meal tolerance tests with insulin Aspart from
the estimation data enable a comparison to the simulated IAsp MTTs.
Bridging Strategy
The bridging concept links the mapped properties of a new insulin analogue
into the integrated model enabling a simulation of meal tolerance tests. The
simulation uses ”cloned” subjects for the integrated model that is not replaced
by the new insulin. A cloned subject consists of individual parameters esti-
mated in the integrated model and a set of mean parameters describing the
new parts of the model.
It would have been optimal to sample from parameter distributions in or-
der to create new subjects in a MTT, but the separate model estimation did
not establish a parameter correlation structure. A sampling from two separate
parameter distributions (insulin and glucose) would potentially result in pa-
rameter sets that were physiologically infeasible and not representative for a
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T2DM population. In order to retain inter-individual variation in simulations
the cloning approach was used.
The bridging strategy requires two insulin Aspart components to be de-
veloped:
• a population PK model for insulin Aspart
• a transfer function converting insulin Aspart concentration into action-
equivalent concentration of human insulin
The estimation of a PK model for IAsp and a transfer function should be
completely decoupled from the integrated model estimation data. The PK
model and transfer function are the topics for the next sections.
8.1 Aspart Pharmacokinetic Model
The development of the pharmacokinetic model for insulin Aspart was a part
of a different Novo Nordisk project and was carried out by Andreas Velsing
Groth and Lene Alifrangis, BioModelling, Novo Nordisk A/S.
A PK model for insulin Aspart had previously been published by Clausen
et al. [2006]. This model was based on the chemical dissolution process for the
protaminated crystals and a one compartment structure for the insulin dis-
position with first order elimination. The parameter estimate for distribution
volume is unphysiologically high, however clearance is comparable to litera-
ture values. Furthermore, the rate constants for the dissolution process are
slow which introduces a large degree of accumulation which seems unrealistic
in a multiple dose setting.
The estimation data were Novo Nordisk conducted trials using IAsp in
different premix ratios and initially both single-dose and steady-state data
were included for the estimation. The trials selected in the analysis are listed
in Table 8.1. The trials were not exclusively clamp trials which deviate from
the bridging strategy but only PK data was used so the deviation was minor.
Trial Population Ratio #Subjects
ANA-046 T2 NM30 13
ANA-1199 T2 Aspart 36
BIAsp-1086 HV NM30, NM50, NM70 32
BIAsp-1318 T1 NM30, NM70 26
BIAsp-1526 T2 NM50, NM70 72
BIAsp-1746 T1 NM30, NM50, NM70 32
Table 8.1: Trials included in the Insulin Aspart PK Model
The structural model previously reported and also used as basis for the
modelling is a two compartment model for absorption and a single compart-
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ment model for distribution. The model can include a reverse dissolution
process as also shown in Figure 8.1.
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Figure 8.1: Structural model for biphasic insulin Aspart
The modelling analysis encountered several issues, which are also encoun-
tered in other PK models for biphasic insulin. The sampling focuses on the
peak after an injection which primarily provides information on the fast com-
ponent. Some trials also used pure insulin Aspart which adds reliable infor-
mation on the fast component.
The choice of error model also highly affects the estimation of the slow
absorption process. By using a proportional error model increased weight is
put on low concentrations. The sparse sampling, the choice of premixes, and
error model all complicate estimation of the slow component in the model.
The use of steady state data in the estimation requires a calculation of
the amount of accumulation. An explicit calculation was not possible and the
steady-state data had to be discarded due to numerical problems with the
calculation of the accumulation. The consequence was that only single dose
data was used for the parameter estimation.
Parameter F KAS [/min] KAF [/min] KEX [/min] VEX [liter/kg]
Value 1 0.000783 0.0253 0.00997 1.36
Table 8.2: Estimated parameters in the insulin Aspart PK Model
The estimated parameters for the PK model are shown in Table 8.2. A high
volume of distribution and a low elimination rate constant renders the model
unphysiological. However, the model is able to fit data from several trials
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and it was decided to regard the model as an empirical population absorption
model for insulin Aspart. The model was based on mixture ratios 30, 50 and
70 and the empirical structure should discourage ratios beyond this range.
8.2 Transfer Function - Insulin Aspart
The simulation with IAsp treatments based on the integrated model requires
a function able to translate the action of insulin Aspart into corresponding
concentrations of human insulin. This section deals with the estimation of
this function.
Clamp experiments are used to quantify the effect of a new insulin analogue
and typically these trials include comparator insulin. The clamp experiment
thus provides four profiles used in the estimation of the transfer function:
insulin/glucose profile for human insulin treatment and insulin/glucose profile
for insulin Aspart treatment. This enables a translation of the insulin analogue
action into the action of the reference insulin in the integrated model. The
clamp data is presented in Section 4.3 and profiles are shown in Figure 4.4.
The dependent variable in the transfer function is an insulin Aspart con-
centration profile and the output is a concentration profile of human insulin
that would result in an identical action. The modelling approach to the trans-
fer function was PID based where the outcome concentration profile is a linear
combination of a proportional, a delayed and a derivative part of the insulin
Aspart profile. The derivative component can be derived from the profile
whereas the delayed component depends on a delay parameter which was also
a part of the estimation of the transfer function.
The transfer function for insulin Aspart should be relatively simple as
the molecule is nearly identical to human insulin - the only difference being a
faster absorption leading to a faster onset of action [Mudaliar et al., 1999]. The
insulin concentrations are measured in plasma so a difference in absorption has
been accounted for once the measurement is taken. The insulin equivalence in
plasma suggests a transfer function that should directly translate the insulin
Aspart concentration to an identical concentration of human insulin.
In order to determine the transfer function, the structural GIR-response
model should also be estimated. A GIR-response model translates an insulin
concentration into a GIR-response. The GIR-response is typically modelled
with a delayed effect from insulin, but structural form and delay needs to be
inferred statistically.
The GIR-response is based on a insulin action assumption, which was
modelled similar to the minimal model.
dX
dt
= p2(SI · I −X) (8.1)
where X is the insulin action, p2 is a delay parameter and SI is insulin sensi-
tivity.
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Three candidates for GIR models are shown in Equations (8.2)-(8.4)
M1: GIR = X (8.2)
M2: GIR =
EmaxX
1 +X
(8.3)
M3: GIR =
EmaxX
γ
1 +Xγ
(8.4)
The first candidate (M1) is a direct translation from insulin action to
glucose infusion rates. The second and third candidate models assumes a
saturable model structure with a max GIR response of Emax moreover the
third (M3) uses a hill coefficient to alter the slope.
Another factor in the GIR model building was whether to include baselines
for insulin and glucose infusion rates. The GIR baseline can be thought of
as a product of non-insulin dependent elimination and the contribution from
insulin dependent elimination from insulin baseline.
Insulin action as used in the GIR models was determined using the follow-
ing equations that also include the transfer function Tr(·).
Human Insulin:
dX
dt
= p2(SI · IHI −X) (8.5)
Insulin Aspart:
I∗HI = Tr(IIAsp) (8.6)
dX
dt
= p2(SI · I∗HI −X) (8.7)
The equations (8.2-8.7) represent the models that will be used to analyse
the cross-over clamp experiment with simultaneous estimation of the transfer
function. The parameterisation of the transfer function will be as shown in
Equation (8.8).
Tr(IIAsp) =
Proportional︷ ︸︸ ︷
C1 · IIAsp +
Delayed︷ ︸︸ ︷
C2 · IDIAsp +
Derivative︷ ︸︸ ︷
C3 · dIIAsp
dt
(8.8)
dIDIAsp
dt
= IIAsp − τ · IDIAsp (8.9)
The transfer function consists of three scaling constants (Cx) and a delay
parameter (τ) needed to create the integral part. The derivative component
(
dIIAsp
dt ) is determined with a smoothing algorithm a priori. The determination
of the derivative was performed using the loess algorithm in S-Plus, which
implicitly relies on a choice of smoothing factor.
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Differences in potency and/or delay between the insulin analogue and hu-
man insulin should be encompassed by the structure of the transfer function.
If the two insulins have different potency, a simple scaling factor in the transfer
function will correct the difference in SI .
If the two insulins have different delayed effects, the relationship is difficult
to derive from equations. It is clear that a true difference in p2 between the
insulins is not a simple delay or acceleration in I∗HI as it should account for
changed elimination in the effect compartment (∆p2X).
The model building investigated combinations of different parameterisa-
tions of the GIR response (M1-M3), different versions of the transfer function
and inclusion of baselines. The GIR observation used in the modelling was
weight normalised glucose infusion rate which seemed to be physiologically
reasonable.
The final model for the insulin Aspart clamp data did not include a deriva-
tive or integral component of insulin Aspart. The structural model was of the
form M1 seen in Equation (8.2) with baseline values for GIR and insulin
included. The expected unit transfer function was nearly confirmed with a
proportional constant (C1 in Equation (8.8)) estimated to a value of 1.06.
The model included random effects on parameters p2, SI and also on GIR
baseline.
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Figure 8.2: Simultaneous fits to BHI30 and NM30 using the transfer function
The mean fits can be seen in Figure 8.2. The model fit to human insulin
(BHI30) does not capture the peak whereas the general trend in the tail is
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fitted well. The fit for Aspart GIR is quite good. The simultaneous estima-
tion using both profiles resulted in a transfer function consisting only of a
proportional term of 1.06 which is very close to the physiologically expected
value.
The transfer function and the PK model were now ready to be embedded
in the integrated model.
8.3 Prediction of MTT with Insulin Aspart
An extended version of the integrated model was created by embedding the
mean IAsp population pharmacokinetic model and the transfer function for
insulin Aspart into the integrated model. Individual parameter estimates were
used for the glucose and insulin delivery part of the integrated model but the
IAsp components of the model were driven by mean population parameters.
The trial specific meal functions were kept in the integrated model as
identical meals were served in the cross-over treatments. A simulation of a
completely new trial would require a derivation of meal sizes from the protocol.
The extended integrated model can be seen in Figure 8.3, where the new
parts are shown in grey boxes.
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Figure 8.3: Aspart Simulation Model
The individual covariates (weight and baselines) from the human insulin
arms were reused. The insulin doses were mean doses in order to adhere to
the bridging premises. The cloning approach of parameters combined with
covariates and insulin doses formed the population used in the simulations.
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The MTT experiment assumes a steady-state condition for the subjects,
which was replicated in the simulation with a run-in period of several days
of identical treatments. This should ensure that accumulation has been ac-
counted for and that effects of initial conditions have vanished.
The bridging strategy is evaluated by comparing cross-over treatment arms
with simulations. The treatment regimens that were simulated were:
• 2 daily injections with Novomix30 (ANA)
• 2 daily injections with Novomix70 and a dinner injection with Novomix50
(NM707050 - BIASP)
• 3 daily injections with Novomix70 (NM707070 - BIASP)
The simulated predictions of insulin Aspart, total insulin and glucose are
shown in Figure 8.4. The mean insulin/glucose profiles that were measured in
the MTTs are overlaid with the simulations. Both observations and simulation
are plotted with the standard error of the mean in order to visualise mean
variation.
The assay used in the IAsp MTTs is able to distinguish human insulin
from insulin Aspart, which enables a more specific evaluation of the model
components.
Figure 8.4 is divided into rows according to the three analysed treatment
arms and columns according to measured variable. The first column shows the
concentration of insulin Aspart, the second column shows the total concentra-
tion of insulin and finally the last column shows the glucose concentrations.
NM30
The bidaily NM30 treatment (first row) fits the measured insulin Aspart con-
centrations reasonably well. A misfit is seen at the dinner peak for insulin
Aspart. Total insulin1 concentrations fits peak values nicely but the overnight
level of total insulin is too high. The overnight profile for insulin Aspart fit-
ted so the discrepancy is believed to originate from an overestimated insulin
delivery baseline. The glucose fit show a discrepancy in the same overnight
period but also the lunch peak is under-predicted. The general fit in glucose
is reasonable and variation is within the observed range.
NM707050 & NM707070
For the NM707050 and NM707070 treatment arms, the predicted insulin As-
part profiles are very similar to the measured insulin Aspart levels. The peaks
and trough values for insulin Aspart are captured and only the overnight pe-
riod is a little off. The variation pattern for insulin Aspart seems to be a little
low at peaks.
1Total insulin = endogenous secreted insulin + translated insulin Aspart
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The fits to total insulin shows that the morning levels of insulin are over-
predicted contrary to peak values that are nicely captured.
The corresponding glucose concentrations for the treatments show that
the overnight periods are not predicted adequately. The measured glucose
concentrations show an overnight increase whereas the predictions are flat
until breakfast is served. These mis-predictions propagate into the breakfast
peak which is also under-predicted. The conclusion was that the extended
integrated model was unable to predict the glucose profiles for NM707050 and
NM707070.
The overnight rise in glucose can be caused by poor glycemic control as a
result of low insulin doses or potentially due to the dawn phenomenon that is
linked to growth hormones. Regardless of cause, the measured concentrations
are not captured by the predictions.
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Figure 8.4: Simulation of the MTTs treated with NovoMix
8.3. Prediction of MTT with Insulin Aspart 73
Treatment Differences
A secondary goal with the bridging strategy was a prediction of the differ-
ences between treatments. A comparison between treatments should partially
eliminate the influence of baseline values which have a substantial impact in
the current model.
The BIASP trial included a comparison of treatments NM707070 versus
NM707050. Figure 8.5(a) and 8.5(b) show the glucose profiles for simulated
treaments and the measured. The difference between the profiles should thus
be the prediction of the simulation.
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Figure 8.5: Difference in treatments NM707070/NM707050
The plot in Figure 8.5(c) shows that the difference between measured
profiles cannot be predicted using the difference between simulated profiles.
The measured difference between treatments show that the treatment with
a higher fraction of fast acting insulin is more glucose lowering at dinner time
i.e. the difference NM707050-NM707070 is positive. An interesting point is
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that the treatment with the better overnight coverage NM707050 counter-
intuitively does not provide better overnight glycemic control as expected.
8.4 Aspart Evaluation
In this chapter, the bridging strategy was evaluated using insulin Aspart as a
insulin analogue case. The integrated model was extended with a PK model
and a transfer function for insulin Aspart, which was then used to simulate
cross-over treatments arms from the estimation data. The meal tolerance
test treatments were based on biphasic insulin Aspart in different treatment
regimens.
The result of the simulation was that the prediction for the NM30 treat-
ment in ANA was good with only minor deviations, whereas the predictions of
NM707070 &NM707050 was poor and did not capture the glucose dynamics.
The insulin profiles showed that the baseline insulin delivery was too high and
the overnight drift in glucose was not fitted.
Unfortunately, the conclusion was that the bridging strategy was not suc-
cessful on insulin Aspart when compared to cross-over MTTs from estima-
tion data. A series of questions naturally arose: What caused these mis-
predictions? Could the integrated model be corrected by simple adjustments?
The next section will cover the analysis that was performed in order to map
the cause(s).
CHAPTER 9
Post Modelling Analysis
The evaluation of the bridging approach with insulin Aspart showed that the
glucose profiles in a MTT could not be predicted accurately. This chapter
describes the analyses that were performed to determine any remedies that
could aid in a better model prediction.
A range of analysis was conducted to examine the bridging strategy with
insulin Aspart.
• Insulin Aspart as forcing function
An analysis was conducted where the insulin Aspart PK model was
replaced with the measured insulin Aspart concentrations to avoid any
error to spill over into the predictions. The use of measured profiles in
the model is sometimes denoted as using the observations as a forcing
function.
• Meal function parameterisation
It was raised during the modelling that the estimation of the meal func-
tion potentially would absorb variation from other glucose pathways,
e.g. variations in elimination. In order to evaluate the meal function, a
comparison with a different parameterisation was performed to pinpoint
differences and to detect potential gains by a shift in parameterisation.
The comparator meal function was proposed by Chiara Dalla Man from
the University of Padova, Italy [Man et al., 2002].
• Flexibility
The structural model setup was investigated to determine if the minimal
model structure had sufficient flexibility to fit an overnight increase in
glucose concentrations as observed in the BIASP data. This analysis was
focused on the mean structural model setup and therefore examined on
mean data.
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The analyses were carried out subsequently to the evaluation with insulin
Aspart in order to find remedies for the bridging strategy.
During the preparation of the PhD thesis, a retrospect analysis was con-
ducted that could pinpoint the cause of the mis-predictions to reside either
within the insulin model or the glucose model. The analysis was devised after
the post-modelling analysis had been concluded and solely performed out of
curiosity.
9.1 Insulin Forcing Function
The influence of the insulin Aspart PK model was investigated by repeating
the simulation, but replacing the insulin Aspart PK model with the actual
measured IAsp concentrations. Any error introduced by the insulin Aspart
model was circumvented and the remaining extended integrated model was
kept including insulin/glucose baselines. In order to fulfil the preconditions
of the bridging strategy, the mean of the measured IAsp profile was used as
forcing function.
The results of the simulation can be seen in Figure 9.1. The concentrations
of total insulin in the different treatments are still overestimated in the night
period and the corresponding glucose predictions do not capture the overnight
increase. The simulations are better than the original simulations with the
extended integrated model but far from a successful bridging.
The new simulation with mean insulin Aspart profile as input indicated
that the problem causing the mis-predictions did not reside in the Aspart
PK model as it was still present even though the IAsp PK model had been
replaced.
The outcome of the analysis was that the attention was moved to the
glucose model - specifically the meal function.
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Figure 9.1: Aspart Simulations with Mean Aspart Profile as input
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9.2 Meal Function Parameterisation
The meal function was suspected to play an important role in the mis-predictions.
The glucose appearance and glucose elimination counteract each other and re-
main inseparable in cold glucose experiments, causing the estimation of the
meal function to compensate for elimination, or vice-versa. This section will
cover an analysis that includes a comparison with a different parameterisation
that potentially could have provided a different prediction.
The comparison of parameterisations was initiated after a visit to Padova
University where a different parameterisation of glucose rate of appearance
(RA) was used. The parameterisation was developed on tracer data which
enables determination of unobservable glucose fluxes, e.g. glucose appearance.
The original estimation data was not used for the analysis instead esti-
mation data originated from a meal tolerance test in T1DM patients treated
with Insulin Aspart. The trial compared two different mixture ratios of insulin
Aspart (NM30/NM70) and is briefly described in Appendix F.
Only the breakfast meal was examined to simplify the analysis. The break-
fast meal was selected as it starts from a fasting state and meal accumulation
should be minimal. Both treatment arms were included for all 22 subjects
resulting in a total of 44 glucose profiles being analysed. The glucose pro-
files can be seen in Appendix F.1. A disregarded but still interesting analysis
would be to examine if the three meals from the same day would have equal
absorption properties or if some trend could be determined.
The parameter estimation was performed using the software SAAMII,
which enables Bayesian parameter estimation, but is limited to single sub-
ject modelling.
Model Setup
The model setup was the oral minimal model [Man et al., 2002], also described
below in equations (9.1)-(9.2).
˙G(t) = −(p1 +X(t)) ·G(t) + p1 ·Gb + RA
V
G(0) = Gb (9.1)
˙X(t) = −p2 ·
(
X(t) + SI · (I(t)− Ib)
)
X(0) = 0 (9.2)
where I(t) is a linear interpolation of the measured insulin concentrations
during the MTT.
The parameter estimation included Bayesian priors in combination with
the GEZI index. Priors were used for GEZI and pp2 whereas bioavailability
and glucose distribution volume were fixed (f=0.9 and V=1.45 dl/kg).
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GEZI was used to determine p1 based on SI .
p1 = (GEZI + SI · V · Ib)/V (9.3)
GEZI ∈ N(0.025, 0.00252) (9.4)
pp2 was used as prior for the delay parameter p2.
p2 = (pp2)
2 (9.5)
pp2 ∈ N(0.11, 0.0112) (9.6)
In order to ensure a common frame of reference, the comparisons were per-
formed with identical prior information and parameter boundaries, whenever
possible. The only difference between the models lies within the parameteri-
sation of glucose rate of appearance (RA).
Parameterisations
The two parameterisations for RA are in this thesis named according to their
origin i.e. Padova and Novo Nordisk. An illustration of the two parameteri-
sations can be seen in Figure 9.2.
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Figure 9.2: Illustrations of the different parameterisations
Padova Meal Function
The Padova approach is a flexible piece-wise linear function consisting of seven
knots at specific time points. The time points are pre-defined and are thus
not a part of the estimation process.
The Padova parameterisation can be written mathematically as shown in
Equation (9.7).
RA(t) =
{
ki−1 +
ki−ki−1
ti−ti−1 for ti−1 ≤ t ≤ ti i = 1...7
0 otherwise
(9.7)
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where a pseudo parameter k0 = 0 is used to simplify notation.
The amount of absorbed glucose should be corrected for the body weight
and the bioavailability of the meal and cannot exceed the amount of ingested
glucose. This simple limitation was implemented through an AUC limit. The
knot K3 was not estimated but instead it was a function of the other knots
ensuring that AUC corresponds to ingested meal. The remaining knots were
estimated under the constraint that they must be positive.
The Padova parameterisation allows for a very flexible fit to the glucose
absorption at the cost of many parameters (knots). The definition of the time
points is based on an assumption of the profile and thus affects the estimation.
Novo Nordisk Meal Function
The Novo Nordisk approach to glucose appearance from meals have previously
been modelled in this thesis with the ”meal function” as a double exponential
function as shown in Equations (9.8)- (9.9).
MS1 = MA1 · (MK1 +MK2) ·
(
MK1
MK2
)
(9.8)
RA(t) = MS1 · e−MK1·t(1− e−MK2·t) (9.9)
where MA1 is the glucose amount in the meal and the parameters MK1
and MK2 are rate constants.
For the integrated model, the meal function was assumed to have identical
rate constants which were also used in this analysis.
MS∗1 = 2 ·MA1 ·MK1 (9.10)
RA(t) = MS∗1 · e−MK1·t(1− e−MK1·t) (9.11)
To make the comparison fair, the meal function needed to be revised. The
Padova approach relies on that the entire meal is digested within five hours.
In order to use the identical constraint for the Novo Nordisk parameterisation,
the normalisation constant was altered.
A new normalisation constant MS2 was calculated that ensured that the
glucose from available weight normalised meal corresponded to the AUC of
the meal function.
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f ·Dose
BW
= MS2 ·
∫ 5·60
t=0
MealFunction dt (9.12)
= MS2 ·
∫ 300
t=0
e−MK1∗t(1− e−MK1∗t)dt (9.13)
MS2 =
f ·Dose
BW
/( 1
MK1
(
1
2
− e−MK1∗300 + 1
2
e−2∗MK1∗300)
)
(9.14)
RA(t) = MS2 · e−MK1·t(1− e−MK1·t) (9.15)
Using the normalisation in Equation (9.14) the AUCs for the Padova pa-
rameterisation and the Novo Nordisk parameterisation were identical.
Table 9.1 contains a summary of the two models. The main interest should
be that the two models have identical insulin/glucose model with identical
constraints and priors and only differ in parameterisations of the glucose ap-
pearance rate.
Model Parameter Bayesian Fixed RA Covariates
Padova SI GEZI,pp2 V, f k1 . . . k7 Dose,I(t),BW,Ib
Novo Nordisk SI GEZI,pp2 V, f MK1 Dose,I(t),BW,Ib
Table 9.1: Parameter comparison between the two methods.
Parameterisations Results
The mean estimated profiles for the Padova and Novo Nordisk parameterisa-
tion are shown in Figures 9.3(a) and 9.3(b).
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Figure 9.3: Median Rate of Appearance with 10% and 90% quantiles
Visually, it can be seen that the estimated glucose appearances after a meal
are similar with the two parameterisations. Both estimate maximum glucose
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appearance to be approx 6 mg/(kg · min) at around time=100 min. The
more flexible Padova RA shows a slightly more rapid incline but otherwise
the RA profiles seem similar. It was concluded that it was highly unlikely
that the Padova approach would have resulted in a better prediction with the
integrated model.
The verification that the meal function parameterisation on cold data was
on par with current parameterisation led to a continued analysis of the inte-
grated model - specifically the structural glucose model.
9.3 Flexibility of the Minimal Model
The analysis of the glucose component of the integrated model continued
with an analysis of the flexibility of the minimal model. It was of interest to
determine if the structure of the minimal model had sufficient flexibility to fit
the glucose profiles seen in the BIASP trial.
The analysis was conducted on mean data instead of individual profiles to
focus on the structural dynamics for glucose and to facilitate faster computa-
tion. It was visually evaluated that the mean profiles were representative for
the glucose dynamics in each treatment arm. The mean profiles can be seen
in the data profiles in Appendix D.
The minimal model used in the modelling is shown in Equations (9.16)-
(9.17):
˙G(t) = U + SG(Gb −G)− SI ·G · (X(t)− Ib) (9.16)
˙X(t) = p2 ·
(
I(t)−X) (9.17)
The integrated model used a literature value for the SG of 0.0055 min
−1
whereas the remaining parameters were estimated. The flexibility of the min-
imal model was examined by altering the set of parameters being estimated.
Glucose baseline was also included into parameters that could be estimated,
but not insulin baseline as insulin was regarded as input. The fits should be
used to evaluate the flexibility of the estimated parameters. Four different
model types were constructed by changing which parameters were estimated.
The four model types are summarised in Table 9.2
The models were estimated on each treatment arm, but also tested in
a bridging setup. The bridging setup tested whether a set of parameters
estimated on human insulin profiles could be used to predict the glucose profile
for IAsp treatment arms.
Figure 9.4 shows the fits from the four different model types to each of
the treatment arms. The fits to observations are good but a closer inspection
reveals differences during the night period. The two model types that estimate
Gb are clearly better at fitting the increasing glucose whereas the models with
Gb extracted from data are not capturing the increase.
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Figure 9.4: Fits pr. arm with different model types
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Model Estimated Fixed
Normal SI , p2, U SG, G
∗
b , I
∗
b
SemiSG SI , p2, U , SG G
∗
b , I
∗
b
SemiGB SI , p2, U , Gb SG, I
∗
b
Full SI , p2, U , SG, Gb I
∗
b
U includes all meal related parameters MAp,MKp
* denotes extracted from data
Table 9.2: Models tested for flexibility and bridging performance
The bridging setup was investigated by estimating the model types on hu-
man insulin treatment arms and reusing the parameters to predict the glucose
profile for IAsp. The bridged glucose profiles can be seen for treatments NM30,
NM707050 and NM707070 in Figure 9.5 where model types are denoted as in
Figure 9.4.
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Figure 9.5: Bridging Mean Profiles from Human Insulin to insulin Aspart
9.4. Post Modelling Round-Up 85
The profile for NM30 (see Figure 9.5(a)) has problems with peaks that
could be linked to the estimated meal function but the overnight period is
actually captured.
The predicted glucose profiles for NM707050 and NM707070 are out of
scale. The only model type that nearly predicts in the correct range is the
SemiSG model. The dynamics for the models that estimate Gb display correct
dynamics compared to observations for the overnight period but are 2-3 mM
low.
The challenging overnight increase in glucose was best fitted with model
types that estimated Gb but these models performed inferior in the bridging
setup.
The conclusion for the analysis of the structural model was that the mini-
mal model has sufficient flexibility to fit the glucose profiles. However, it was
also concluded that the same set of parameters cannot be used to bridge from
human insulin profiles to IAsp profiles.
9.4 Post Modelling Round-Up
The post modelling analysis aimed at pinpointing the cause(s) for the mis-
prediction of the extended integrated model. The analysis included replacing
the insulin Aspart PK model with the mean IAsp observations, a comparison
of two different glucose appearance parameterisations, and investigating the
flexibility of the minimal model.
The use of mean insulin Aspart observations as input showed that a po-
tential error in the Aspart PK model was not the cause of the mis-predictions.
The insulin predictions were marginally better but no improvement was seen
in glucose predictions.
The second analysis targeted the glucose appearance from a meal and was
a comparison between two different parameterisations. The comparison did
not reveal relevant differences in the estimated glucose rate of appearance.
The conclusion was that the prediction from the integrated model would not
change by replacing the meal function.
The final analysis examined the structural model for the glucose dynamics.
Mean profiles of glucose and insulin were modelled and tested in a bridging
setup in order to verify that the minimal model was sufficiently flexible to fit
the increasing glucose overnight. The result was that the minimal model was
able to fit the mean glucose profiles adequately when Gb was also estimated.
However, the bridging setup was not successful for NM707050/NM707070 IAsp
treatment arms but nearly accurately predicted the NM30 treatment arm.
The post-modelling analysis was not successful in establishing a remedy
for the bridging strategy. Conclusions acquited some components but a clari-
fication of the problem was not obtained.
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During the preparation of the PhD thesis, a new analysis was conceived
that potentially could identify the problem area.
Retrospect
The condensation of the results from the insulin/glucose modelling, initiated
new ideas and analyses that could pinpoint functional components of the ex-
tended integrated model.
Despite warnings against initiating modelling work in the final part of
the PhD programme, an analysis was started where the insulin part was
completely bypassed. The analysis focused on treatments NM707050 and
NM707070 which were simulated using the individually measured total in-
sulin profiles as input. The preconditions of the bridging strategy are thus
not adhered.
The remaining components in the model were meal function, glucose dy-
namics, and insulin action.
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Figure 9.6: Simulation of NM707050 and NM707070 using individual total
insulin as input
The simulation profiles in Figure 9.6 clearly show that the simulation cap-
tures the overnight increase in glucose. The dinner and breakfast glucose peaks
are also nicely predicted whereas the lunch peak is slightly over-predicted.
The new simulation revealed an important point that has not previously
been determined. The cause of the mis-predictions was initially believed to
reside in the glucose part of the integrated model but the retrospect simulation
showed that the insulin model coupled with the bridging strategy was the likely
problem. Especially, the use of the mean insulin profiles was a candidate.
The estimation of the integrated model was performed on human insulin
with individual insulin profiles but the bridging setup does not include an
individualisation of insulin (IAsp) profiles. The inherent correlation between
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insulin sensitivity, insulin dose/titration and insulin baseline was estimated on
human insulin and this relationship was broken when the mean insulin Aspart
PK model was embedded in the integrated model as a part of the bridging
strategy.
The minimal model is centred around baselines (insulin/glucose) which
implicitly means that the term (X − Ib) in the insulin dependent glucose
elimination can become negative, which interpreted physiologically, means an
appearance of glucose. The mean IAsp profile used in simulations could imply
that this artefact scenario does not happen and no glucose increase will occur
in periods of insulin levels lower than insulin baseline.
Perspectives from this knowledge are that insulin profiles need to be indi-
vidualised, which could be obtained through a scaling using AUCs from human
insulin profiles or insulin doses. A challenge lies in combining this individual
scaling with the new treatment regimen specified in the protocol. The corre-
lation between dose and insulin sensitivity etc. determined on human insulin
should be maintained while still adhering to a new titration scheme specified
in the protocol.

CHAPTER 10
Discussion and Conclusion
The framework for the modelling was aimed at predicting 24-hour glucose
profiles for a new insulin analogue. The integrated model for insulin and
glucose was to be estimated on human insulin and the properties of the new
insulin analogue were to be embedded using insulin properties determined
from clamp experiments including PK studies.
10.1 Discussion
The data selected for the model building was trials with 24-hour meal tolerance
tests performed in T2DM patients treated with human insulin and insulin
Aspart in a cross-over design. The meal tolerance tests setting included three
meals, insulin injections and measurements of insulin, glucose and C-peptide
concentrations. Initially, three trials were selected: ANA, BIASP and NN2211
which meant a total of 42 T2DM subjects.
The NN2211 trial population was discarded during the model building
due to discrepancies between the population of the NN2211 trial and the
other trial populations. The exclusion was based on results from a range of
evaluation scenarios that were compared to literature values. The results from
the simulations were in accordance with the difference in populations also seen
in the demographics summary. A valid exclusion should have been based on
the demographics prior to modelling and not on evaluations performed during
model development.
The integrated model for insulin and glucose was estimated by NONMEM
V based on system dynamics described by ordinary differential equations and
non-linear mixed effects to capture inter-individual and inter-occasion vari-
ability. The multivariate structure with insulin and glucose, the dimension of
the parameter space, and the numerical solution of differential equations led
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to a decision of separate estimation of two sub models: An insulin sub model
and a glucose sub model.
Insulin Model
The insulin sub model was estimated using measured glucose concentrations
as input for the insulin secretion. Pre-hepatic insulin secretion was initially
modelled using C-peptide concentrations which aided in the determination
of pre-hepatic insulin secretion but also required a model for hepatic insulin
extraction. The model building established that it was more robust to link
glucose observations to systemic insulin delivery rates than to pre-hepatic
insulin secretion. Consequently, the information in the C-peptide profiles was
disregarded in the current model setup but it could be interesting to explore
methods of including C-peptide information in an insulin delivery model.
The insulin model had several parameters fixed to literature values due to
identifiability issues. The fixation approach restricts the mixed effects estima-
tion and also enforces a structure from a potentially different population into
the model. Alternative solutions could be to perform a Bayesian parameter
estimation with a prior instead to allow for more flexibility or even better to
obtain tracer data enabling accurate estimation of internal processes.
The choice of human insulin as reference insulin in the bridging strategy
implied that estimation of indistinguishable pathways was required. This was
due to the fact that administered insulin and endogenously secreted insulin
are identical. An estimation of the secretion/delivery component on insulin
Aspart data would allow for a separation and a better estimation of the basal
level. However, this solution violates the preconditions of the bridging strategy
for insulin Aspart.
The insulin model building showed the strength of deconvolution based
on stochastic differential equations in a population setting when the insulin
model was simplified using deconvolved pre-hepatic insulin secretion rates as
input. The deconvolved insulin secretion rates were replaced with an insulin
secretion model at a later stage.
The insulin model was able to fit the human insulin profiles in estima-
tion data. Several model candidates were tested during model development
including variations within: insulin secretion/delivery, absorption structures,
non-linear hepatic insulin extraction, and inter-injection variability.
Glucose Model
The glucose sub model structure was inspired from the oral minimal model
and included a meal function to describe glucose appearance after ingestion of
meals. The trial specific meal function in the final model was a compromise
between robustness in parameter estimation but also in accordance with the
experimental setting where identical meals were served to all patients.
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The model structure was tested for a two compartment extension but this
was found not be statistically significant. Furthermore, the model had volume
of distribution volume fixed to 17 litres and SG fixed to 0.0055 min
−1. Both
values were selected from a range of literature values from T2DM patients.
The fixation of SG was a result of the evaluation scenarios (clamp and
ITT) that guided the model building towards a more insulin sensitive model.
The comparisons with literature values for insulin driven elimination fractions
were complicated by the different experimental setups used in literature. The
glucose model selection was primarily based on properties in correspondence
with literature, increased insulin driven elimination fraction motivated by the
evaluation scenarios and naturally the model fit to estimation data. The final
glucose model was in accordance with reported glucose effectiveness, was more
insulin sensitive than previous models evaluated in simulation scenarios and
fitted estimation data well.
Integrated Model
An integrated model for insulin and glucose was created by combining the two
sub models that had been estimated on human insulin. The integrated model
was evaluated in the glucose clamp and ITT scenarios previously described
but also in a insulin dose sensitivity analysis.
The evaluation scenarios motivated a shift in the model structure during
model development and also raised important points. A critical issue with the
evaluation scenarios based on external sources is the assumption of identical
populations and negligible influence from uncontrollable factors in the experi-
ments. For these reasons, the scenarios were selected to specifically match the
T2DM population and with relatively simple experimental setups.
The estimation data was predicted nicely with the integrated model which
led to the conclusion that the separate estimation had not caused biased pre-
dictions.
The clamp simulation showed that the insulin action peaked in the correct
time period and the GIRmax value indicated a correct estimation of insulin
absorption and insulin action. The glucose clamp simulation also showed that
the tail of the simulated GIR profiles were under-predicted. A comparison
with a NPH insulin action profile as illustrated in Heinemann [2004, p.39]
supported decreasing insulin action after a peak at around 4 hours as seen in
the simulated profiles.
An additional evaluation was a subjective sensitivity analysis on insulin
doses where it was concluded that the integrated did not show as low glu-
cose concentrations as intuitively expected. A potential cause could be that
the physiology behaves differently in the lower ranges and these are not well
extrapolated by the integrated model or as previously indicated that the in-
tegrated model has issues with insulin sensitivity.
The evaluation scenarios targeted different components of the integrated
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model: insulin absorption, insulin sensitivity, glucose effectiveness, and glucose
elimination. The scenarios were essential in evaluating the integrated model
for an overall qualification.
The integrated model was able to predict estimation data and the results
from evaluation scenarios pinpointed issues but none with crucial impact.
Bridging
The bridging setup was evaluated on insulin Aspart from cross-over trial arms
and required a PK model for IAsp and a transfer function for the analogue
action. The PK model was supplied by a different project and the transfer
function was developed based on clamp data.
The transfer function setup using a PID approach proved reliable in rela-
tion to estimating a scaling parameter in accordance with physiology. How-
ever, the simultaneous fit for GIR profiles showed an underestimated peak
value for GIRHI . The insulin Aspart transfer function should be simple and
less complex than the expected transfer functions for future analogues. The
transfer function setup was analysed with focus on embedding long acting in-
sulin analogues. The setup provided good interchangeability for insulin ana-
logues with altered potency but accelerated/delayed action was more complex
to accommodate. This is unfortunate as the bridging strategy specifically tar-
gets new insulin analogues with prolonged action. Further research should
focus on testing the PID approach to assess performance or investigate other
methods.
An extended integrated model was created by embedding the PK model
and a transfer function for insulin Aspart. The ”cloning” approach was used
for parameters in the extended integrated model where parameters were either
reused from the HI integrated model or mean population parameters for IAsp
components. The cloning approach ensured that the simulation was not based
on subjects that had unphysiological parameters. Preferably, a simulation
should consist of a sampling from the parameter distributions in order to create
synthetic subjects representative for the estimation inter-individual variation.
However, the sampling approach was not used due to parameter correlation
structures that could not be determined in the separate sub model estimation
. The cloning approach restricts the simulation to the estimation foundation
i.e. 29 subjects but a small plausible subject population was weighted over a
large potentially unrealistic synthetic population.
The evaluation of the extended integrated model showed that the insulin
components fitted the evaluation data well. The fits for insulin Aspart profiles
showed good fits for breakfast and lunch but slightly under-predicted in the
overnight period. The profiles for total insulin had problems with the basal
level of total insulin prior to breakfast that was over-predicted in all three
profiles. The remaining parts of the profiles were captured nicely.
The glucose observations showed an overnight drift that was not captured
10.1. Discussion 93
in any of the simulations. A corresponding drift was not observed in the esti-
mation data and potential causes could be lack of overnight insulin coverage
or dawn phenomenon which is driven by growth hormone. The discrepancy
in glucose dynamics between estimation and evaluation data tests the model
dynamics in an extrapolation setting which is always cumbersome. The con-
clusion was that the ultimate goal of a bridging for insulin Aspart from clamp
to 24-hour glucose profiles was not successful.
The modelling objective included both the prediction of absolute glucose
profiles but also a secondary objective with the simulation of differences be-
tween treatments. Simulation of differences should hopefully eliminate the
influence of insulin and glucose baselines. The evaluation of the simulated
difference in treatments (NM707050 and NM707070) showed that the model
predictions for treatment differences were not comparable to the observed
data. The excursions of the observed differences were of higher amplitude
than the simulated. Furthermore, the simulated and observed difference did
not have the same sign in periods. This means that there was a discrepancy
between which treatment was the most glucose lowering in the observed and
simulated profiles.
Post Modelling Analysis
The post modelling analyses aimed at pinpointing the cause(s) for the mis-
predictions from the extended integrated model. The analyses included re-
placing the insulin Aspart PK model, investigating the meal function, and
evaluating sufficient flexibility of the minimal model setup.
The influence from the IAsp PK model was investigated by replacing the
PK model with the observed mean IAsp concentration profiles. This had no
substantial effect on the glucose predictions and it was concluded that the
cause was not in the mean IAsp PK model.
The post modelling analysis of meal glucose appearances indicated that
a shift in parameterisation would not have changed the predictions but a
literature evaluation of the glucose appearance e.g. from a tracer experiment
Basu et al. [2003]; Toffolo et al. [2006a] would add further certainty about this
model component.
The flexibility of the minimal model structure was also investigated and it
was found that sufficient flexibility was available for predicting the overnight
increase in glucose. The crucial point was the split between parameters being
estimated and parameters being directly extracted from data. By estimating
Gb, the overnight glucose increase was fitted but the ability to bridge from
HI profiles to IAsp profiles was lost. The analysis was initiated based on
the hypothesis that the cause of poor predictive power resided in the glucose
model but no specific issues were found.
The analysis performed in retrospect in which the entire insulin part of
the extended integrated model was replaced by observed individual profiles
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indicated that the problem was the mean insulin profiles used in the simula-
tions. The model was estimated using individual human insulin profiles and
was simulated using a mean PK model with mean doses (pr. weight). The
simulated profiles from the retrospect analysis clearly show that using indi-
vidualised insulin profiles then the glucose part of the integrated model is able
to accurately predict the overnight increase in glucose.
Future work could be to bridge information on individual insulin require-
ments coupled with the protocol specifications for the new meal tolerance test
into a simulation.
Another interesting challenge lies in investigating the model proposed by
Silber et al. [2007]. The model structure has been showed in publications to
be able to fit IVGTT and OGTT experiments and a MTT model version was
mentioned in the PhD thesis of Petra Jauslin-Stetina [Jauslin-Stetina, 2008].
Similar has an insulin-glucose model been published from the Padova group by
Man et al. [2007b] that was approved by the FDA as an ”In Silico” platform
for testing of closed loop systems [Kovatchev et al., 2009].
Both models have high potential but are un-identifiable on current data.
So an analysis should be conducted into which parameters to reuse and which
to fix from the publications, in order to adjust the models to current goals.
10.2 Conclusion
The development of a mathematical model for insulin and glucose aiming
at predicting 24-hour glucose profiles from meal tolerance tests with a new
insulin analogue has proven to contain many challenges: identifiability issues,
availability/validity of evaluation scenarios, limitations in software, endless
combinations of model candidates, adherence to preconditions stemming from
drug development, and finally a complex biological system that was estimated
based on limited insight from noisy observations.
The modelling approach has shown a method for the model building with
interim evaluation for determining the performance of a model. The cloning
of subjects enables a generic population that can be used in simulation as a
substitute for a full sampling of inter-individual and inter-occasion variability.
The extended integrated model for simulation of insulin Aspart treatments
did not perform adequately. Specifically, did the model predictions not capture
a substantial increase in overnight glucose concentrations. The PK model
for insulin Aspart predicted mean and variance in the correct range but a
retrospect analysis showed that the use of a mean insulin model could be an
important factor in the mis-predictions.
Future work should focus on including tracer data or other detailed data
for obtaining a more accurate integrated model. Also, a method to bridge
individual insulin requirements in the clamp experiment into the MTT simu-
lation in order to individualise new insulin analogue treatments could form an
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interesting path forward in the bridging strategy. With regards to modelling
techniques, the emerging use of stochastic differential equations (SDEs) also
provides a modelling framework with appealing properties. Potentially, the
diurnal variations could be tracked with SDEs and consequently modelled.
The main experiences from the thesis are that abundant information was
available with the challenge to dissect into relevant and useful information.
The modelling and simulation of insulin/glucose required insight into multi-
ple academic fields spanning from statistics, engineering, human physiology,
and computer science - A combination that have been both challenging and
rewarding.
We have not succeeded in answering all our problems. The answers
we have found only serve to raise a whole set of new questions. In
some ways we feel we are as confused as ever, but we believe we
are confused on a higher level and about more important things.
Posted outside the mathematics reading room, Tromsø University. Personally, I discov-
ered the quote in Bernt Øksendals book [Øksendal, 1998].

Part II
PSM: Population Stochastic
Modelling
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CHAPTER 11
Introduction and Motivation
The goal of the PhD project was the development of predictive tools for de-
signing new insulins and treatment regimens and the first part of the PhD
thesis focussed on the formulation of an integrated model based on ordinary
differential equations for the prediction of 24-hour glucose profiles.
In parallel to the model building, a different part of the thesis aimed
at methodology - specifically the development of a software package able to
handle mixed effects models based on stochastic differential equations (SDEs).
The package should be aimed at PK/PD modelling with features for bolus
dosing and infusion but should also be applicable to other modelling fields.
Statistical mixed effects models are widely used within drug development
both within classic statistical analysis of dose-response models but also as ran-
dom coefficients models in PK/PD modelling. The strength of mixed effects
models is typically formulated as the ability to separate sources of variabil-
ity into: Random variation within a class and variation between classes. In
PK/PD modelling, a class is typically an individual but methodology is not
limited to individuals other classes could be occasions, trials or centres etc.
[Davidian and Giltinan, 1995; Pinheiro and Bates, 2002].
PK/PD modelling is an emerging field within industry and academia and
also motivated by the FDA in both guidance papers [FDA, 1999] but also
implicitly in the critical path initiative that endorses a modernising of scientific
tools used in drug development.
The increased use of mixed effects in PK/PD modelling has been facilitated
by NONMEM [Sheiner and Beal, 1994]. NONMEM is the golden standard of
today for analysis of ODE based models using mixed effects in parameters.
It is widely used due to its flexibility and capabilities for dosing and infusion.
Other programs exists (Monolix, S-Adapt, SPK, etc. [Bauer et al., 2007;
Dartois et al., 2007]) which provide different capabilities such as optimisation
methods or user interfaces.
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The modelling approach used in PK/PD is typically based on models using
ODEs to describe the system dynamics. These models can be both non-linear
and/or include random effects to account for inter-individual variation. An
ODE based model is deterministic in system dynamics which is in contrast to
the variation present in many experiments. A deterministic description is char-
acterised by the fact that such a model is able to predict future concentrations
without any error provided that the initial conditions are known. However,
PK/PD models are often aimed at complex systems where a complete descrip-
tion is beyond current knowledge. The inevitable model misspecification and
natural variation within the experiment calls for a more flexible model type.
The motivation to combine mixed effects and SDEs is not new. The articles
by Overgaard et al. [2005] and Tornøe et al. [2005] both target the combination
of SDEs and mixed effects, with a proposed estimation scheme and an imple-
mentation based on an explicit description of the Kalman Filter in NONMEM.
A drawback of the NONMEM implementation is that it requires a detailed
level of understanding to specify the required filtering equations however the
implementation benefits from the PK/PD features already present in NON-
MEM and it’s computational speed. Markov Chain Monte Carlo (MCMC)
methods are often used as an alternative to the Kalman Filter approach but
comes at the cost of increased computational requirements [Ditlevsen and
Gaetano, 2005].
The extension to SDEs from ODEs enables a split of the prediction error
into system error and observation error [Tornøe et al., 2004]. The use of SDEs
is still being explored and investigated but the perspectives within PK/PD
modelling are promising. SDEs are in particular useful for systems with nat-
ural occurring variation or model misspecification. A strong motivation point
for SDEs is the capability to correctly handle correlated residuals which are
often disregarded even though traditional statistical tests are invalidated due
to wrong assumptions on residuals. Furthermore, SDEs provides a systematic
framework for pinpointing model deficiencies [Kristensen et al., 2005].
The desired features for a program include model specification using SDEs,
dosing/infusion capabilities, multivariate observations, and inclusion of mixed
effects to handle inter-individual variation.
CTSM [Kristensen et al., 2004] is a software program aimed at models
based on SDEs and was developed at DTU-IMM by Niels Rode Kristensen
as an extension of programs developed by Henrik Melgaard and Henrik Mad-
sen [Melgaard and Madsen, 1993]. CTSM uses the Kalman Filter approach
to handle SDEs but does not include capabilities for mixed effects or doses.
CTSM was used as the basis for the development and Niels Rode Kristensen
also provided highly valuable input for the development, which was greatly
appreciated.
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A prototype package for Matlab was built in 2006 and formed the basis
for the article found in Paper B. The article describes the estimation method-
ology and provides an application of the prototype where pre-hapetic insulin
secretion rates were determined via deconvolution.
The next chapters will describe the mathematical methodology and the
R-package that was the result of the development process. The applications
of the package are then presented and discussed.

CHAPTER 12
Methodology
The mathematical methodology used in the development of the PSM package
is described in this chapter. The methodology will focus on parameter esti-
mation and not on simulation and smoothing. For a detailed description of
simulation with SDE models - see [Kloeden and Platen, 2000; Iacus, 2008],
and for smoothing - see the CTSM Mathematics Guide [Kristensen, 2003] or
Gelb et al. [1982].
The parameter estimation for models based on SDEs extended with mixed
effects has previously been described in detail and the current description will
focus on the highlights of the method [Overgaard et al., 2005; Overgaard,
2006; Tornøe, 2005]. Furthermore, a full description of stochastic differential
equations is beyond the scope of the thesis which only focuses on a subset
of SDEs handled through the Itoˆ interpretation [Øksendal, 1998; Madsen and
Holst, 2000].
12.1 SDE Models for a Single Subject
Solutions for single subject ODE based models can in simple cases be derived
analytically but often numerical integrators are needed to determine an ap-
proximate solution. The solution for SDE based models cannot be derived via
deterministic solution of system dynamics but a more complicated method is
needed to handle the separation of measurement and system error.
The single subject model for observations is typically described by a set of
differential equations that describe system dynamics and a link from internal
states to observations. The SDE state space model can in general form be
written as follows:
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dxt
dt
=f(xt,φ,ut, t)dt+ σ(ut, t,φ)dωt (12.1)
yk =g(xk,φ,uk, tk) + ek (12.2)
where k = 1...n, t ∈ R is time, xt ∈ Rs is a vector of state variables, ut ∈ Rm
is a vector of input variables, yk = ytk ∈ Rl is a vector of output variables.
f(·) and g(·) are functions (potentially non-linear). The measurement error is
assumed to be normal distributed as ek ∈N(0,S(uk, tk,θ)). ω is a standard
Wiener with ωt−ωs ∈N(0, |t− s|). φ is the parameter vector for indidual i.
This SDE model specification can be seen to collapse into an ODE system
when the scaling diffusion term σ(·) tends to zero. This property enables
parameter interpretation/comparison between ODE and SDE models and also
enables the use of statistical methods to test the extension to SDE.
The notation for SDEs shown here are for the non-linear case with fur-
ther simplifications being possible for the linear case. The SDEs used in this
thesis are continuous-discrete as shown in Equations (12.1)-(12.2) which only
constitutes a small subset of the complete class of SDEs.
The main assumptions in the current class of SDEs are: Gaussian mea-
surement error and state independent diffusion term. The main difference
to many other applications of SDEs is the measurement error that is often
discarded to enable other estimation methods e.g. [Picchini et al., 2008].
The calculation of residuals in an ODE based model can be performed by
a numerical solution of the deterministic ODE system resulting in a set of
predictions which subsequently can be compared to the actual observations.
ek = yk − yˆk|k0 (12.3)
In an SDE model, the residual is a result of measurement error and accu-
mulated system error since last observation. The residual for an SDE one-step
prediction is shown in Equation (12.4).
k = yk − yˆk|k−1 (12.4)
The prediction for the internal states should be updated accordingly to the
observed system error in order to predict the next observation. The problem
now consists of how to divide the residual in measurement and system error
such that the states can be updated accordingly.
This problem can be solved by using the Kalman Filter [Kalman, 1960]
which provides a minimum-variance estimator for the internal states. The
Kalman Filter is a filtering method that recursively predicts and updates esti-
mates of internal states by weighting the measurement error S(·) and system
error σ(·).
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The Kalman Filter is based on a propagation of first and second order mo-
ments for the estimates of the internal states. For linear models, the Kalman
Filter provides the exact solution but for non-linear models the Extended
Kalman Filter uses a linearization by which the solution becomes approxi-
mate.
The likelihood for the parameters in the SDE based model can be formu-
lated using the conditional densities for the residuals [Kristensen, 2003].
L(φ|Yn) = p(Yn|φi,S,σ) =
 n∏
j=2
p(yj |Yj−1,φ, ·)
 p(y1|φ, ·) (12.5)
where Yj denotes all observations up to time tj and n denotes the total number
of observations.
The residuals are can be assumed to follow a multivariate Gaussian dis-
tribution given a set of conditions stemming from linear state space model,
Gaussian measurement error and Wiener noise.
k ∈N(0,Rk|k−1) (12.6)
The Kalman filter is used to calculate the conditional mean and conditional
covariance for the residuals which is then used to calculate the likelihood via
the multivariate Gaussian distribution.
L(φ|Yn) =
 n∏
j=2
exp
(
−12Tj R−1j|j−1j
)
√
|2piRj|j−1|
 p(y1|φ) (12.7)
The likelihood for parameters φ given observations can for the single sub-
ject case be specified as in Equation (12.7). The residuals and conditional
covariances are determined using the Kalman Filter and form the basis for
the maximum likelihood parameter estimation.
The likelihood for a given parameter vector given the observation profile
for a single individual can now be determined and parameter estimation facili-
tated through maximum likelihood estimation. The extension to mixed effects
models is described in the next section.
12.2 Mixed Effects
Non-linear mixed effects modelling is an appealing alternative to the classic
two-stage method for PK/PD modelling. The ability to handle multiple sparse
data profiles or unbalanced designs provides a robust method - especially
useful for PK/PD modelling [FDA, 1999]. Data analysed in clinical trials
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often originates from multiple individuals that have been exposed to one or
more treatments. The non-linear mixed effects model provides a framework
to characterise variation within individuals and between individuals.
The term mixed effects refers to two kinds of effects being estimated: fixed
effects that describe the mean parameters and random effects that describe
variation between individuals forming a distribution around the mean param-
eter. Furthermore, the framework facilitates the use of covariates in order to
explain inter-individual variation e.g. the parameter describing volume of dis-
tribution can often be partially explained using weight or BMI. The individual
parameter vector is a function of fixed effects, random effects and covariates
as shown in general notation below:
φi = h(θ,ηi,Zi) (12.8)
where the parameter φi denotes the parameter vector for individual i.
θ are the fixed effects, Zi are the covariates for individual i, and ηi are
the random effects. It is generally assumed that ηi ∈ N(0,Ω) to simplify
derivation of the likelihood.
The distribution of individual parameters e.g. estimates for volume are
often found to be log-normal distributed. This leads to a common parameter-
isation as shown in Equation (12.9) which also guarantees that sign shift do
not occur from the influence of random effects.
φ = θ · exp (η) (12.9)
The estimation methods for non-linear mixed effects methods are numer-
ous and hold different properties. Pinheiro and Bates [Pinheiro and Bates,
2002] describe a number of approaches for parameter estimation in nlme-
models.
The parameter estimation is based on maximum likelihood optimisation
of the marginal likelihood. A simpler notation is obtained by introducing a
hyper parameter Ψ which contains parameters relevant for θ,S and σ. First
the marginal likelihood for Ψ and Ω is formulated based on the distribution
functions for the first and second stage models denoted p1 and p2, respec-
tively. The first stage model describes the intra-individual variation i.e. the
single subject model and the second stage model describes the inter-individual
variation from the random effects.
Li(Ψ,Ω|Yi) = p(Yi|Ψ,Ω) =
∫
p(Yi,ηi|Ψ,Ω)dηi
=
∫
p1(Yi|ηi,Ψ) p2(ηi|Ω)dηi (12.10)
where Yi is the observations for individual i.
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The likelihood function for the entire population can be formulated as
shown in Equation (12.11).
L(Ψ,Ω|Y) =
N∏
i=1
∫
p1(Yi|Ψ,ηi)p2(ηi|Ω)dηi (12.11)
By introducing li as the a posteori log-likelihood function for individual i
the likelihood can be formulated. It relies on Gaussian conditional densities
for the residuals and a Gaussian distribution of the random effects.
li(Ψ,ηi) = −
1
2
ni∑
j=1
(
TijR
−1
i(j|j−1)ij + log |2piRi(j|j−1)|
)
− 1
2
ηTi Ω
−1ηi −
1
2
l log |2piΩ| (12.12)
L(Ψ,Ω|Y) =
N∏
i=1
∫
exp(li(Ψ,ηi))dηi (12.13)
A closed-form solution to Equation (12.13) is rarely available and one solu-
tion method is to approximate the integral. A detailed derivation of different
approximations are found in Wang [2007] and in the NONMEM User guide
part VII [Beal and Sheiner, 1998].
The FOCE approximation was chosen for this development project as it
was the standard in PK/PD development at the time. The FOCE approxima-
tion is based on the Laplace approximation which can be used to approximate
complex integrals. It is based on a second order Taylor expansion of the inte-
grand around maximum (q′(xo) = 0) and can in a general notation be written
as below. ∫
p(x)dx =
∫
exp(q(x))dx ≈ p(x0) ·
√
2pi
−q′′(x0) (12.14)
For a detailed description and derivation of the Laplace approximation see
Wang [2007].
The Laplace approximation requires the Hessian of the log-integrand (q(x)),
which is not easy to calculate precisely due to computational issues.
The marginal likelihood function in (12.13) is solved by approximating li
with a second-order Taylor expansion, where the expansion is made around
the value η∗i that maximizes li(ηi) in the value l
∗
i . At this optimum the first
derivative ∇li
∣∣
η∗i
= 0 and the population likelihood function can be reduced
to:
L(θ,S,σ,Ω|Y) ≈
N∏
i=1
∣∣∣∣−∆l∗i2pi
∣∣∣∣− 12 exp(l∗i ) (12.15)
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as shown in Appendix of Paper B. The approximation of the Hessian at the op-
timum ∆l∗i is obtained using the First-Order Conditional Estimation (FOCE)
method, which results in the Hessian approximation seen in Equation (12.16).
∆l∗i ≈ −
ni∑
j=1
(
∇TijR−1i(j|j−1)∇ij
)
−Ω−1 , ∇ij = ∂
∂ηi
ij
∣∣∣
η∗i
(12.16)
The first order derivative of the one-step prediction with relation to random
effects needs to be derived numerically through the single subject estimation.
12.3 Summary
The methodology for combining stochastic differential equations with mixed
effects has been described covering both a single subject estimation handled
using the Kalman Filter and a mixed effects part where the marginal likelihood
was approximated with FOCE.
The intra-individual variation is handled using the (extended) Kalman Fil-
ter that recursively updates/predicts states according to model specification
and incoming observations. The Kalman filter is based on a series of assump-
tions on Gaussian distributions: Measurement error and increments in the
diffusion term (Wiener Process). Other preconditions are state independent
diffusion term and additive measurement error. The Kalman filter can be
derived as first and second order moments of the estimated states facilitated
by a first-order Markov property of the system [Madsen, 2007].
These assumptions can be extended via a log transform of the observations
to obtain a log-normal error model or including input in the diffusion term
to describe the state evolution. The Kalman Filter provides an attractive so-
lution in relation to computational load balanced with restrictions to model
specification. The a posteriori individual likelihood is based on one-step pre-
diction errors from the first stage model with covariances determined in the
Kalman Filter.
The population part of the modelling is achieved with a second stage
model using mixed effects. The mixed effects allow for a description of the
inter-individual variation explained through distributions in parameters. The
random effects are assumed Gaussian and are often used to model log-normal
distributions of parameters which correspond to a physiological interpretation.
Parameter estimation is based on maximum likelihood estimation of the
marginal likelihood which is approximated using a first order Laplace approxi-
mation aided by an optimisation of the a posteriori individual likelihood. The
evaluation of the population likelihood thus relies on individual optimisations
to obtain η∗i . The parameter estimation consequently consists of a nested
optimisations leading to a substantial computational load.
CHAPTER 13
PSM - An R-package
This chapter will describe and introduce PSM i.e. the development of an R-
package. A description of the package was published (Paper A) which also
contained an application where insulin secretion rates were determined using
deconvolution based on stochastic differential equations (SDEs).
The combination of SDEs and mixed effects has already illustrated via
an explicit implementation of the Kalman Filter in NONMEM [Tornøe et al.,
2005] but also as a Matlab Framework (Paper B). However, it was still believed
there was a need for an accessible, simple to use software with PK/PD features.
The NONMEM approach to SDEs is non-trivial to new users, but provides
a flexible and fast framework. In Paper B, a Matlab prototype was presented
which procured valuable experiences and knowledge. Inspiration was also
found in other software programs such as CTSM, WinNonlin, NONMEM,
SAAM, Berkeley Madonna etc. which all features different strengths.
The aim with the program was an accessible software program which could
provide a better start to modelling with SDEs. Several aspects were considered
during the software implementation as for instance:
• Availability to users
• Computational Speed
• Data preparation
• Results handling
13.1 Platform
R was chosen as programming platform due to its open source availability and
its widespread applications in statistical and numerical groups [R Development
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Core Team, 2009]. R is available on most operating systems and its package
system makes it easy for the user to add new functionality to the installation.
Furthermore, R holds functionality for many statistical/mathematical oper-
ations that allowed the development process to focus on implementing new
functionality and not re-implementing basic operations.
The shortcoming of R concerns computational speed - the original aspira-
tion with a software program was a multicore implementation to accommo-
date large scale models. Multicore facilities are available in R but a general
platform-independent framework hidden from the novice user was not avail-
able. The available multicore options would thus require configuring and setup
according to the specific setup. The multicore facilities could have been imple-
mented at several different levels such as numerical gradient calculations but
also in individual contribution to the marginal likelihood. The compromise
between a widely and easily available program and a multicore implementation
tipped in favour of availability.
The software implementation in R consists of a set of functions that can
perform tasks on models based on SDEs extended with mixed effects. The
main functionality consists of simulation, parameter estimation and smoothing
supplemented with utilities that aid in general model building. The functions
and utilities were compiled in an R-package named PSM - an abbreviation
for ”Population Stochastic Modelling”. The R package system makes it easy
for the user to access the package which also contains documentation and
introductory examples.
A main strength of R comes with capabilities in pre- and post-modelling
process. The pre-processing of data with the compilation of data-file(s) can be
performed within R and likewise for the post-processing of modelling results.
The statistical analysis and visual presentation of results can be handled with
R - overall enabling a single environment for the entire modelling process.
The package aimed at a separation of the dosing information and the ob-
servations as opposed to NONMEM where dosing and observations are con-
tained in the same data file. This enables an easy change of dosing regimen
or observations without having to regenerate a data file.
13.2 User Interface
The model specification is done through user defined functions for the individ-
ual parts of the model definition. The model functions/elements are collected
in a list. The functions rely on component names to extract model compo-
nents from the list which can be the cause for problems with misspelling. A
more compact and user friendly notation like the notation in the nlme package
Pinheiro et al. [2009] could be beneficial but it does not allow for the desired
flexibility.
Linear and non-linear models are specified differently as the linear case can
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use simpler estimation techniques. For a linear system, the system matrices
suffice but for non-linear models, the full model specification and derivatives
needs to be specified. The program doesn’t utilise automatic differentiation
but numerical versions of the gradient/jacobian can be implemented which is
slower but often a more accessible solution for new users.
In Table 13.1 a general model specification for a non-linear model is shown.
The component Functions is a list containing system dynamics, observation
link and corresponding derivatives. The remaining components are all R func-
tions that return a specific component.
Components Arguments Output
Functions x, u, t,φ List with f(·), g(·), df(·), and dg(·)
X0 t, φ, u Matrix with initial state condition(s)
SIG φ Matrix with diffusion scaling term σ
S φ Matrix with residual covariance
h η, θ, covar Vector with individualised parameters φ
ModelPar Θ List with fixed effects θ and inter individ-
ual variation Ω
Table 13.1: Non-linear Model Elements in PSM
A large part of the methodology relies on matrix operations whereby it
is only natural that the model is specified using matrix syntax. The matrix
syntax can often induce dimension problems which the software program tries
to prevent by thoroughly checking dimension validity prior to any calculations
are started.
13.3 Package Components
The package provides functionality for simulation, parameter estimation and
smoothing. The simulation algorithm is a simple Euler scheme but has been
shown to perform similar to other discretization schemes in SDE simulation
[Iacus, 2008].
Smoothing is the optimal reconstruction of estimated states based on all
available data and thus constitutes a post-processing functionality which can
be highly useful.
The internal calculations in the package are formed by components such
as optimisation algorithms, gradient calculations and low-level implementa-
tions for faster computations. These components are described for a complete
understanding of the package which could be used to extend functionality or
better understand results.
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Optimisation and Gradients
The parameter estimation relies on a optimisation of the objective function
which is:
− logL(Θ) ≈
N∑
i=1
(
1
2
log
∣∣∣∣−∆li2pi
∣∣∣∣− li) (13.1)
where Θ denotes the combined set of parameters i.e. both fixed effects
and variance parameters.
The nested optimisations required in FOCE are performed per individual
to determine the optimal random effects (η∗i ) for a given set of population
parameters (θ). Consequently, a single evaluation of the objective function
value induces N individual optimisations of random effects.
The estimation of population parameters is performed using a quasi-Newton
based optimisation based on function values and gradients. The default op-
timiser in the package is optim but hands-on experience has shown that the
ucminf [Nielsen and Mortensen, 2009] optimiser performs better. The optimi-
sation per individual is restricted according to the specified covariance matrix
Ω decrease computational load.
Gradients are determined numerically with finite differences. Typically, a
simple forward difference is used but for the -gradient in Equation (12.16)
central differencing is used.
Physiological parameter boundaries are not uncommon and constrained
optimisation has been implemented to ensure robust parameter estimation.
Parameter boundaries are implemented for the population parameters using
the logit transformation extended with a penalty function to avoid flat gradi-
ents near parameter boundaries. [Kristensen, 2003, p.25].
Parameter Uncertainty
The parameter uncertainty for the estimated parameters is based on the ob-
served Fischer Information Matrix originating from the Hessian of the negative
log likelihood defined as [Pawitan, 2001; Madsen, 2007]:
j(Θ) = − ∂
2
∂Θ∂ΘT
logL(Θ) = −∇2 logL(Θ) (13.2)
If the parameters maximizing the likelihood function are called Θˆ they will
asymptotically have the distribution
Θˆ ∼ N(Θ, j(Θˆ)−1). (13.3)
This is used in PSM to provide a 95% Wald confidence interval, stan-
dard error and correlation matrix for the estimates. The Hessian is evaluated
numerically using hessian in the numDeriv package.
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Low-level
The package implementation in R is supplemented with an implementation
of core elements in low-level languages for faster computation. The Kalman
Filter for linear models was implemented in FORTRAN and linked with R
which increased performance substantially.
The Extended Kalman Filter was also considered but not straight forward
and not implemented as it required system calls from FORTRAN back to R
to evaluate model components in each time step.
13.4 Accessibility and User Guide
The package was named PSM and was published via R’s package system
(CRAN). The users now easily add PSM to their installation via R-package
system and start exploring SDEs combined with mixed effects through user
guides and examples.
The user guide can be accessed via R by excuting the command:
> vignette("PSM")

CHAPTER 14
Applications
PSM is still a new package and applications mostly originate from personal
work. External applications are still to be published but it is the hope that
these will come.
14.1 Deconvolution
Deconvolution is used within signal processing to determine the original signal
from a noisy and convolved signal for linear systems. The term deconvolution
used here in this thesis only refers to the concept of determining an underlying
signal from noisy observations.
Deconvolution in this thesis is based on an approach using stochastic dif-
ferential equations to quantify the original signal. The deconvolution of a
signal is obtained by including an additional state in the model specification.
The new state represents the unknown signal e.g. an incoming flow or a time-
varying parameter. The dynamic of the new state is modelled solely with a
stochastic component i.e. the state is modelled as a random walk or more
advanced as an integrated random walk.
Parallel to the parameter estimation, the most likely trajectory for the
state is determined by the Kalman Filter. The unknown state can now be
assessed by examining the filtered or smoothed estimate of the state.
The determination of the pre-hepatic insulin secretion rates (ISRs) given
the C-peptide measurements is presented in Paper B and was also presented
at the PAGE conference in 2008 [Klim et al., 2008]. The deconvolution of pre-
hepatic insulin secretion rates were also utilised in the insulin/glucose model
building that is described in this thesis.
The deconvolution approach for the insulin secretion can briefly be de-
scribed as: An additional state modelled with a random walk was included
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into the C-peptide dynamical system. The model setup is the standard Van
Cauter C-peptide model [Cauter et al., 1992] extended into a SDE system
with ISR modelled as a separate state.
A strong feature of the deconvolution method is that the Kalman Filter
determines both the most likely outcome of the random walk but also the
corresponding uncertainty. The uncertainties can be used to evaluate the
deconvolved profile and aid in a mathematical description.
ISR
C1 C2
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k2ke
1
Figure 14.1: ISR Deconvolution Model
The standard two compartment C-peptide model can be seen in Figure
14.1 with ISR shown as input rate into the central compartment. The rate
parameters were based on covariates but variance components (S,σ and Ω)
and initial C-peptide concentration were estimated.
In Figure 14.2, the deconvolved insulin secretion rates for two subjects are
shown. The estimated state uncertainty is also presented as the grey shadow
on the profile. It can be seen how the top profile exhibits clear peaks at meal
times where as the bottom profile displays a more flat secretion profile.
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Figure 14.2: Deconvolved ISR
Hepatic Extraction
By extending the C-peptide model into a multidimensional model for C-
peptide and insulin, a quantification of the hepatic extraction rates for insulin
becomes feasible [Vølund et al., 1987; Bergman and Lovejoy, 1997]. The model
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can be seen in Figure 14.3(a) and the devonlved profiles for hepatic extraction
rates over time can be seen in Figure 14.3(b).
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(a) Insulin/C-peptide Model Setup
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Figure 14.3: Deconvolution of hepatic extraction rate
In this application, the multivariate capability of PSM is illustrated and it
is shown how the population approach can support estimation of parameters
e.g. ke.
The quantification of hepatic extraction could be used to determine factors
controlling hepatic extraction which could have been useful in combination
with the insulin secretion model building (Chapter 5).
Intervention Model
The deconvolution example of insulin secretion rates was extended further in
Paper A with an intervention model. A common trait for the physiologically
anticipated insulin secretion rate and also the deconvolved ISR is that the
profiles do not have mean zero which contradicts assumptions for Wiener
noise. An intervention model was tested for the ISR case by including an
impulse signal for every meal lasting 30 min. The signal amplification and
delay was estimated to build a base model for insulin secretion.
The model structure used here uses the stochastic differential equations to
compensate for unmodelled variation in insulin secretion rates.
In Figure 14.4, the C-peptide fits and deconvolved ISR can be seen. The
red dashed line represents the deterministic model fit. The deconvolved ran-
dom walk is in much better correspondence with the Wiener assumption than
the original ISR deconvolution.
The model assumes identical responses for the insulin secretion response
for all three meals. The intervention model could easily be extended such
that each meal had its own insulin response. The deconvolved insulin secre-
tion profiles are not different from previously determined but the estimated
model can now be used in simulation scenarios as opposed to the previous
deconvolution model where insulin secretion rates were pure random walks.
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Figure 14.4: Intervention Model
The intervention model shows an application where SDEs are used to
compensate for model mis-specification and/or natural variation.
14.2 Nonlinear Deconvolution with Non
Negativity Constraint
The deconvolution technique was presented in articles and at conferences and
main arguments against the approach was the loose assumption with the ran-
dom walk. However, some constraints from physiological knowledge are not
guarantied with the random walk but the approach gives maximum flexibility.
A simulation study of the glucose minimal model was used to illustrate that
deconvolution can also be applied for non-linear models and a non-negativity
constraint was added for the deconvolved glucose appearances.
Glucose profiles were simulated using predefined model structures for the
insulin and glucose appearance. The analysis aimed at a deconvolution of
the glucose appearance based on simulated glucose observations and insulin
profile.
The glucose appearance was modelled as an additional state but introduced
in the glucose dynamics using an exponential function to ensure a positive
glucose appearance.
Three different deconvolution scenarios were tested where noise levels and
sampling times were varied. The parameter estimation only included variance
components whereas system parameters were reused from the simulation.
The non-negativity constraint implemented using the exponential function
led to an unstable model. As a solution the parameter estimation was revised
such that tight parameter boundaries were gradually loosened and estimation
re-started in last optimum until optimum no longer resided on parameter
boundaries.
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Figure 14.5: Non-linear deconvolution with the Minimal Model
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Figure 14.6: Results from non-linear deconvolution in a scenario with sampling
every 10th min and a 2% coefficient of variation
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The predicted observations and glucose appearance rates are shown in Fig-
ure 14.6. Three profiles are shown to illustrate the variation from measurement
noise. The smoothed profiles would have been preferred but due to the unsta-
ble model, this was not feasible. The correspondence between the simulated
glucose appearance and the filtered estimate is reasonable. However, the per-
formance decreases rapidly with lower sampling rates and/or increasing noise
levels which have not been shown here.
The glucose appearance example shows that deconvolution can also be ap-
plied in non-linear cases which is not possible in classic signal processing and
time series analysis. Furthermore, it shows an implementation of a physiolog-
ical constraint implemented via the exponential function.
14.3 Input Error Propagation
Dynamic models do frequently include inputs e.g. temperature or insulin
concentrations. The measured input often enters into the model dynamics
without means to account for measurement error. The input measurement
error should be distinguished from the observations measurement error as
the later is accounted for in the observation link. The input measurement
error will propagate through the model dynamics and potentially influence
predictions.
The hypothesis is that an SDE model should be better at handling the
input error propagating through the model via the system noise component
than an ODE model.
An analysis was conducted in order to assess the influence of input error
in two different scenarios: a linear and a non-linear model. The model setups
were tested with different combinations of measurement error on observations
and input. The analysis was not an analytical derivation of the influence but
two different scenarios were the effects were analysed.
Linear Model
The linear model was a one-compartment model with a known drug infusion.
The simulations were performed without any noise components. Afterwards,
measurement noise was added to both input and observation profiles. The
model parameters (V and K) were estimated from noisy profiles with both
an ODE model and an SDE model. The sampling of input and observations
noise followed by an ODE and SDE estimation that were repeated multiple
times after which the distributions of estimated parameters were compared to
the parameter values from the simulation.
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Figure 14.7: Parameter histograms for the linear model
Nonlinear Model
The non-linear model was the glucose minimal model depicted in Figure
14.5(a). The glucose appearance was assumed to be known both during sim-
ulation and estimation. The main interest was in parameters SG, SI , and
p2. The measurements noise levels were 20% for the input and 1% for the
observations. The levels were chosen such that input error was much larger
than measurement error. Samples of the glucose and insulin profiles from the
estimation are shown in Figure 14.8.
The sampling of noise followed by parameter estimation was repeated 500
times for the non-linear model using both an ODE and a SDE model type.
The results can be seen in Table 14.1 that shows nearly identical parameter
estimates from the SDE and ODE estimation. SG and SI are correspondingly
over- and under-estimated which is in agreement with a simulation analysis
by Cobelli et al. [1999]. The standard deviations for the parameters do not
differ substantially but the residual variation is lower for the SDE estimation
and corresponds with the used variation in the simulation.
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Figure 14.8: Sample profiles from estimation with the non-linear model
SIM SDE.Par SDE.SD SDE.Rel ODE.Par ODE.SD ODE.Rel
SG 5.50E-03 1.06E-02 3.41E-03 191.84 1.06E-02 3.62E-03 191.90
SI 2.82E-05 2.62E-05 1.59E-06 92.84 2.58E-05 1.66E-06 91.61
p2 3.00E-02 3.33E-02 9.69E-04 111.16 3.33E-02 1.03E-03 111.12
S 1.00E-04 1.01E-04 5.04E-05 100.57 1.14E-04 5.31E-05 114.21
Table 14.1: Parameter estimates from the non-linear model
The analysis of the influence of input error with regards to estimation
with ODE and SDE based models showed that dynamic parameter estimates
were alike but the residual variation was estimated correctly with SDEs. A
hypothesis on why the parameters did not show a difference could be that
Gaussian noise with mean zero was used on input and measurements profiles
which in combination with the sampling scheme resulted in a cancelation of
effects such that the estimates from ODE and SDE did not differ significantly.
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14.4 Organic Growth
The applications presented so far have all been personal but PSM is also used
by others. Unfortunately have the results not been published yet. PSM is
being used by PhD student Anders Strathe, Copenhagen University for the
modelling of animal growth in order to determine optimal time for slaughter.
The growth in pigs is usually modelled with ordinary differential equations
which are unable to capture the natural variation present especially during dis-
ease periods. The growth of a pig that becomes ill will pause or even result in
a decrease. The ODE setup is not able to handle disease situations. The SDE
model provides a framework where the variations in slaughter time due to dis-
eases are handled correctly and not just as measurement error. Furthermore,
does the population approach suits the problem nicely with the population of
pigs being analysed.
Another interesting field is the analysis of bacterial growth. Analysis of
bacterial growth is used for determining effects of anti-bacterial treatments
[Philipsen et al., 2008]. The bacterial growth is analysed in multiple of iden-
tical populations with identical initial conditions whereby the growth is es-
tablished as a mean growth. The population approach provides an attractive
method to determine growth patterns for each bacterial population and an
estimate for the variation present between bacterial populations.

CHAPTER 15
Discussion and Conclusion
The development of PSM was motivated by a need for a program able to han-
dle stochastic differential equations (SDEs) combined with mixed effects. A
further aim was the inclusion of features for PK/PD modelling. An aspiration
was a program that would constitute a softer introduction to modelling with
SDEs.
15.1 Discussion
The combination of SDEs and mixed was shown to be possible by explicit
implementation of the Kalman Filter in NONMEM by Tornøe et al. [2005].
The lack of software providing an easy platform for modelling with SDEs and
mixed effects motivated the development of the R-package PSM.
The package implements the combination of SDEs and mixed effects with
focus on PK/PD modelling but the aspiration was that the package should
also be used in areas such as energy, financial or biological. The motivation to
use SDEs in modelling includes the ability to decompose the error into system
and measurement noise whereby correlated residuals are handled correctly.
Furthermore, the SDEs enable a modelling framework that can be used for
pinpointing model deficiencies.
The package was implemented in R which makes it widely and easily acces-
sible to users. The accessibility is an important point in relation to teaching
or other research groups where PSM makes SDE models easier to approach
and to use as a modelling alternative to standard ODE models.
The PSM package includes functionality for model building, utilities, doc-
umentation and tutorials. The model specification is syntax sensitive with
regards to types or dimension mismatch. In order to help users, a validation
check has been implemented in the package which captures the most common
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mistakes and returns meaningful error messages. However, a simpler notation
would have been preferable but model flexibility was weighted over notation.
The choice of R comes at a compromise in computational time compared
to other programming languages and will potentially hinder applications on
large scale problems. A multicore implementation was not a implemented as
a general platform independent implementation was not possible. Thereby,
the scope of the package becomes more of an introductory program to SDEs
and mixed effects than aimed at large scale problems. A benefit of using
R as platform comes with the integration in an existing data and statistics
environment that allows the user to perform most modelling tasks within the
same program.
The methodology implemented is the Kalman Filter used to handle stochas-
tic differential equations supplemented with the FOCE approximation to en-
able maximum likelihood estimation in combination with the mixed effects.
The Kalman Filter and the FOCE approximation both can be exchanged with
other methods but form a good balance between numerical performance and
assumptions.
The current open source implementation also allows users to experiment
with the code. New optimisers or gradient methods can be tested by replacing
the relevant modules. The intention was a modular program that can be used
as a framework to test new ideas.
A range of applications have been presented that illustrates the potential
of PSM. Deconvolution based on stochastic differential equations has been an
application for insulin secretion rates or glucose appearance rates using the
non-negativity constraint.
The intervention model showed the strength of SDEs to account for mis-
specification in a secretion model where natural variation was present. The
example resembles deconvolution but the result is an estimated model also
useful in a simulation setting.
The application on input error propagation showed the benefit of modelling
with SDEs in models using inputs. The result showed that the parameter es-
timates were nearly identical but only in the SDE estimation was the residual
variation estimated correctly. A hypothesis for the only slightly differing pa-
rameters estimates could be that the noise structure had mean zero and was
sampled too frequently whereby potential propagation was cancelled out.
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15.2 Conclusion
A useful, documented program able to handle stochastic differential equations
extended with mixed effects was developed and is freely available in R.
The implementation enables a wide range of models which holds benefits
for PK/PD models where inter-individual variation is handled but natural
variation or model misspecification are often inevitable.
The current applications are nearly all from authors of the PSM package
but it is believed that the program will facilitate the emerging use of SDEs
both in PK/PD model development as well as in other scientific fields.
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